

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

New England Journal of Medicine

365, 2484-2496

DOI: [10.1056/nejmoa1103799](https://doi.org/10.1056/nejmoa1103799)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 441.	0.6	30
2	Decreased Parietal Cortex Activity during Mental Rotation in Children with Congenital Hypothyroidism. Neuroendocrinology, 2009, 89, 56-65.	1.2	19
3	Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. Endocrinology, 2012, 153, 1593-1602.	1.4	248
4	Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model. Clinical Cancer Research, 2012, 18, 6306-6314.	3.2	56
5	The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncology, 2012, 8, 1135-1147.	1.1	21
6	Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors. Current Clinical Pharmacology, 2012, 7, 137-145.	0.2	36
7	Immunotherapy in ovarian cancer. Human Vaccines and Immunotherapeutics, 2012, 8, 1179-1191.	1.4	48
8	Bevacizumab in Ovarian Cancer. New England Journal of Medicine, 2012, 366, 1256-1258.	13.9	3
9	Bevacizumab in endometrial cancer treatment. Expert Opinion on Biological Therapy, 2012, 12, 649-658.	1.4	15
10	Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. British Journal of Cancer, 2012, 107, 360-369.	2.9	29
11	Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. British Journal of Cancer, 2012, 107, 1327-1336.	2.9	24
12	First-line bevacizumab for ovarian cancerâ€”new standard of care?. Nature Reviews Clinical Oncology, 2012, 9, 194-196.	12.5	9
13	A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta OncolÃ³gica, 2012, 51, 797-804.	0.8	55
14	A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission. Clinical Cancer Research, 2012, 18, 6509-6518.	3.2	104
15	Enhanced mechanical properties and <i>in vitro</i> cell response of surface mechanical attrition treated pure titanium. Journal of Biomaterials Applications, 2012, 27, 113-118.	1.2	15
16	Revisiting the Complexity of the Ovarian Cancer Microenvironmentâ€”Clinical Implications for Treatment Strategies. Molecular Cancer Research, 2012, 10, 1254-1264.	1.5	40
17	Management of Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1420.	3.8	12
18	Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Review of Obstetrics and Gynecology, 2012, 7, 413-419.	0.4	16

#	ARTICLE	IF	CITATIONS
19	Doublet Chemotherapy in the Elderly Patient With Ovarian Cancer. <i>Oncologist</i> , 2012, 17, 1450-1460.	1.9	11
20	Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up. <i>Pathology Research International</i> , 2012, 2012, 1-8.	1.4	10
21	Molecular/Genetic Therapies in Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 156-172.	0.6	21
23	Clinical Trials in Elderly Ovarian Cancer Patients – Does It Make Sense?. <i>Onkologie</i> , 2012, 35, 73-74.	1.1	2
26	“Author TBD” Radical Collaboration in Contemporary Biomedical Research. <i>Philosophy of Science</i> , 2012, 79, 845-858.	0.5	41
29	Ten-Year Relative Survival for Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2012, 120, 612-618.	1.2	265
30	An Overview of Current Diagnosis and Treatment in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S2-S4.	1.2	12
31	Ovarian Cancer, Version 3.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1339-1349.	2.3	151
32	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1081-1087.	2.3	208
33	The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 3775-3783.	0.9	12
34	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>Yearbook of Medicine</i> , 2012, 2012, 130-131.	0.1	0
35	First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) – a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. <i>Annals of Oncology</i> , 2012, 23, 2613-2619.	0.6	26
36	Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies. <i>Journal of Clinical Oncology</i> , 2012, 30, 4026-4034.	0.8	201
37	Vertical Pathway Targeting in Cancer Therapy. <i>Advances in Pharmacology</i> , 2012, 65, 1-26.	1.2	15
38	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S118-29.	1.0	194
39	Antiangiogenic Therapy for Cancer: An Update. <i>Pharmacotherapy</i> , 2012, 32, 1095-1111.	1.2	163
41	Clinical trials and future potential of targeted therapy for ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2012, 17, 430-440.	1.0	36
42	AERIO News in brief. <i>Onkologie</i> , 2012, 14, 491-494.	0.2	0

#	ARTICLE	IF	CITATIONS
44	Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 229-239.	1.0	34
45	Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?. <i>Gynecologic Oncology</i> , 2012, 127, 362-366.	0.6	9
46	OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2039-2045.	0.8	1,188
47	Pelvic malignancies in older patients: New drugs in the elderly?. <i>Journal of Geriatric Oncology</i> , 2012, 3, S22-S23.	0.5	0
48	Biologic Therapies and Personalized Medicine in Gynecologic Malignancies. <i>Obstetrics and Gynecology Clinics of North America</i> , 2012, 39, 131-144.	0.7	2
49	Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2012, 39, 269-283.	0.7	8
50	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. <i>Neoplasia</i> , 2012, 14, 994-IN1.	2.3	103
51	Is There a Role for Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer Off-Protocol?. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2012, 5, 48-50.	0.1	0
52	Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. <i>Annals of Oncology</i> , 2012, 23, 3104-3110.	0.6	48
54	Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 361.	1.1	43
55	A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2012, 5, 17.	1.3	1
56	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , 2012, 5, 23.	1.3	29
57	Current Status and Future Directions of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 645-663.	0.6	43
58	Bevacizumab Combination Therapy. <i>Drugs</i> , 2012, 72, 917-930.	4.9	9
59	Bevacizumab in Ovarian Cancer. <i>Drugs</i> , 2012, 72, 931-936.	4.9	6
60	Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review). <i>Oncology Reports</i> , 2012, 28, 395-408.	1.2	18
61	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. <i>Nature Biotechnology</i> , 2012, 30, 648-657.	9.4	95
62	Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 224-242.	2.0	8

#	ARTICLE	IF	CITATIONS
63	The role of interleukin-6 in gynaecological malignancies. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 333-342.	3.2	25
64	Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer. <i>Journal of Proteome Research</i> , 2012, 11, 4605-4614.	1.8	48
65	Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1382-1392.	13.9	1,595
66	Surgery for Relapsed Ovarian Cancer: When Should it Be Offered?. <i>Current Oncology Reports</i> , 2012, 14, 539-543.	1.8	20
67	Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?. <i>Current Oncology Reports</i> , 2012, 14, 483-485.	1.8	0
68	Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents. <i>Current Oncology Reports</i> , 2012, 14, 509-518.	1.8	9
69	Ovarian cancer stem cells: elusive targets for chemotherapy. <i>Medical Oncology</i> , 2012, 29, 3400-3408.	1.2	19
70	Bevacizumab in the Treatment of Ovarian Cancer. <i>Advances in Therapy</i> , 2012, 29, 723-735.	1.3	33
72	Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma. <i>Results in Immunology</i> , 2012, 2, 190-195.	2.2	15
73	Emerging drugs for cervical cancer. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 203-218.	1.0	14
74	Antiangiogenic therapy—evolving view based on clinical trial results. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 297-303.	12.5	137
75	Are there candidates for high-dose chemotherapy in ovarian carcinoma?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 87.	3.5	7
76	Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature. <i>PLoS ONE</i> , 2012, 7, e35629.	1.1	19
77	ZNF385B and VEGFA Are Strongly Differentially Expressed in Serous Ovarian Carcinomas and Correlate with Survival. <i>PLoS ONE</i> , 2012, 7, e46317.	1.1	40
78	Ovarian cancer stem cells. <i>Neoplasma</i> , 2012, 59, 747-755.	0.7	42
79	Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape. <i>Frontiers in Immunology</i> , 2012, 3, 21.	2.2	148
80	Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions. <i>Current Angiogenesis</i> , 2012, 1, 266-276.	0.1	0
81	Biologicals in the Upfront Treatment of Ovarian Cancer: Focus on Bevacizumab and Poly (ADP-Ribose) Polymerase Inhibitors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 340-344.	1.8	2

#	ARTICLE	IF	CITATIONS
82	Recent advances in systemic treatments for ovarian cancer. <i>Cancer Imaging</i> , 2012, 12, 305-309.	1.2	7
83	Lessons Learned from the Bevacizumab Experience. <i>Cancer Control</i> , 2012, 19, 309-316.	0.7	23
84	Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer: a systematic review. <i>Journal of Hematological Malignancies</i> , 2012, 2, .	0.0	4
85	Clinical utility of targeted treatments in the management of epithelial ovarian cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 233.	3.0	4
86	Ovarian cancer: emerging molecular-targeted therapies. <i>Biologics: Targets and Therapy</i> , 2012, 6, 147.	3.0	15
87	Angiogenesis: A promising therapeutic target for ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 314-326.	2.0	37
88	Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1576-1586.	1.9	29
89	Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. <i>Journal of Pathology</i> , 2012, 227, 404-416.	2.1	79
90	Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. <i>Journal of Pathology</i> , 2012, 227, 417-430.	2.1	67
91	Novel Antiangiogenic Therapies in Ovarian Cancer. <i>Women's Health</i> , 2012, 8, 447-453.	0.7	3
93	Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers. <i>Current Oncology Reports</i> , 2012, 14, 277-284.	1.8	44
94	Bevacizumab in ovarian cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 83-83.	12.8	1
95	Bevacizumab rechallenge after first line maintenance bevacizumab. <i>Gynecologic Oncology</i> , 2012, 125, 510-511.	0.6	2
96	Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 41-46.	0.6	15
97	Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. <i>Gynecologic Oncology</i> , 2012, 126, 236-240.	0.6	26
98	Therapeutic strategies in epithelial ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 14.	3.5	265
99	Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. <i>Cancer</i> , 2013, 119, 3653-3661.	2.0	42
100	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 149.	1.8	57

#	ARTICLE	IF	CITATIONS
101	Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. <i>Journal of Ovarian Research</i> , 2013, 6, 35.	1.3	20
102	Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 67-82.	0.4	10
103	The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. <i>Updates in Surgery</i> , 2013, 65, 265-270.	0.9	41
104	Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. <i>Journal of Neuro-Oncology</i> , 2013, 114, 191-198.	1.4	29
105	Platelet-Derived Growth Factor Receptor Beta Serum Concentrations during First-Line Therapy in Ovarian Cancer. <i>Oncology</i> , 2013, 85, 69-77.	0.9	5
106	Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 241-245.	0.6	27
107	Mechanisms of resistance to anti-angiogenesis therapies. <i>Biochimie</i> , 2013, 95, 1110-1119.	1.3	113
108	Ovarian Cancer Survival: Steady Improvement, Despite Rhetoric to the Contrary. <i>Current Oncology Reports</i> , 2013, 15, 433-435.	1.8	1
111	Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?. <i>Current Oncology Reports</i> , 2013, 15, 197-200.	1.8	7
112	Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?. <i>Current Oncology Reports</i> , 2013, 15, 201-203.	1.8	1
113	p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1207-1210.	1.2	12
114	Side Effects of Medical Cancer Therapy. , 2013, , .		4
115	Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 22-33.	1.3	11
116	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1-12.	1.1	17
117	Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. <i>European Radiology</i> , 2013, 23, 2916-2925.	2.3	36
118	Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1797-1806.	0.9	12
119	Management of Gynecological Cancers in Older Women. , 2013, , .		2
120	Quality of life in ICON7: need for patients' perspectives. <i>Lancet Oncology</i> , The, 2013, 14, 183-185.	5.1	18

#	ARTICLE	IF	CITATIONS
121	Outcomes for Women Receiving Bevacizumab for Treatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2013, 6, 21-24.	0.1	1
122	Targeting Receptor Tyrosine Kinases in Solid Tumors. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 685-703.	0.6	8
123	Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 161-175.	2.0	38
124	A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 215-220.	0.6	46
125	VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. <i>Pharmacogenomics</i> , 2013, 14, 1659-1667.	0.6	13
126	Influence of tumour micro-environment heterogeneity on therapeutic response. <i>Nature</i> , 2013, 501, 346-354.	13.7	2,093
127	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 236-243.	5.1	125
128	A clinical experience of single agent bevacizumab in relapsing ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 129, 459-462.	0.6	20
129	Controversy in treatment of advanced ovarian cancer. <i>Lancet Oncology</i> , The, 2013, 14, 920-921.	5.1	4
130	Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). <i>Investigational New Drugs</i> , 2013, 31, 1499-1504.	1.2	19
131	NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer. <i>Lancet Oncology</i> , The, 2013, 14, 689-690.	5.1	6
132	Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 3831-3838.	1.3	48
133	A multicenter, randomized trial of flat dosing versus inpatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIIG. <i>Annals of Oncology</i> , 2013, 24, 679-687.	0.6	39
134	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study. <i>Gynecologic Oncology</i> , 2013, 129, 310-317.	0.6	30
135	A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 362-367.	0.6	45
136	Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2013, 130, 295-299.	0.6	9
137	Ovarian Neoplasm Imaging. , 2013, , .		0
138	Ovarian cancer: genomic analysis. <i>Annals of Oncology</i> , 2013, 24, x7-x15.	0.6	29

#	ARTICLE	IF	CITATIONS
139	Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. <i>Translational Proteomics</i> , 2013, 1, 74-86.	1.2	13
140	Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15885-15909.	1.8	105
141	Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2013, 131, 535-540.	0.6	25
142	Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3127-3132.	0.8	25
143	Do we have a new standard in suboptimal debulked disease?. <i>Annals of Oncology</i> , 2013, 24, x37-x40.	0.6	2
144	Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease. <i>Annals of Oncology</i> , 2013, 24, x53-x58.	0.6	39
145	Bevacizumab and ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 133-141.	1.4	45
148	Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. <i>BioDrugs</i> , 2013, 27, 375-392.	2.2	8
149	A review of iniparib in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 399-405.	1.9	4
150	Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. <i>Drug Discovery Today</i> , 2013, 18, 872-879.	3.2	20
151	Targeting IGF-1 signaling pathways in gynecologic malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 307-320.	1.5	58
152	Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. <i>Gynecological Endocrinology</i> , 2013, 29, 811-816.	0.7	10
153	The potential of sunitinib as a therapy in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1671-1686.	1.9	20
154	Tumor-stromal interactions in breast tumor progression – significance of histological heterogeneity of tumor-stromal fibroblasts. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 449-460.	1.5	23
155	Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5788-5797.	3.2	55
156	Investigational agents in development for the treatment of ovarian cancer. <i>Investigational New Drugs</i> , 2013, 31, 213-229.	1.2	25
157	New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential. <i>Clinical Cancer Research</i> , 2013, 19, 961-968.	3.2	287
158	The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 131-140.	1.9	39

#	ARTICLE	IF	CITATIONS
159	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. <i>Cancer Treatment Reviews</i> , 2013, 39, 153-160.	3.4	53
160	Markers of Response for the Antiangiogenic Agent Bevacizumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 1219-1230.	0.8	309
161	Evaluation of Potentially Predictive Markers for Anti-Angiogenic Therapy with Sunitinib in Recurrent Ovarian Cancer Patients. <i>Translational Oncology</i> , 2013, 6, 305-310.	1.7	12
162	Epithelial Ovarian Cancer-Induced Angiogenic Phenotype of Human Omental Microvascular Endothelial Cells May Occur Independently of VEGF Signaling. <i>Translational Oncology</i> , 2013, 6, 703-713.	1.7	40
163	Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer—a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. <i>Gynecologic Oncology</i> , 2013, 129, 463-466.	0.6	37
164	Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2013, 128, 573-578.	0.6	69
165	Targeted cancer therapy “Are the days of systemic chemotherapy numbered?”. <i>Maturitas</i> , 2013, 76, 308-314.	1.0	88
166	The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2013, 128, 391-396.	0.6	56
167	Cáncer de ovario. <i>Medicine</i> , 2013, 11, 1641-1648.	0.0	2
168	A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013, 129, 86-91.	0.6	22
169	Targeted anti-vascular therapies for ovarian cancer: current evidence. <i>British Journal of Cancer</i> , 2013, 108, 250-258.	2.9	64
170	A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2013, 130, 19-24.	0.6	28
171	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. <i>Gynecologic Oncology</i> , 2013, 130, 25-30.	0.6	79
172	Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. <i>Nature Reviews Cancer</i> , 2013, 13, 273-282.	12.8	439
173	Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. <i>Histopathology</i> , 2013, 62, 59-70.	1.6	90
174	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. <i>Cancer Treatment Reviews</i> , 2013, 39, 561-568.	3.4	24
175	Preclinical evaluation of statins as a treatment for ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 129, 417-424.	0.6	46
176	Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects. <i>International Journal of Molecular Sciences</i> , 2013, 14, 640-673.	1.8	20

#	ARTICLE	IF	CITATIONS
177	Axitinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 765-773.	1.9	10
178	Bevacizumab as front-line treatment for newly diagnosed epithelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 123-129.	1.1	6
179	Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 655-666.	0.8	22
180	GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. <i>Clinical and Translational Oncology</i> , 2013, 15, 509-525.	1.2	9
181	Targeting angiopoietin-2 signaling in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 813-825.	1.9	33
182	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 233-247.	1.1	38
183	Latest research and treatment of advanced-stage epithelial ovarian cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 211-224.	12.5	437
184	Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1181-1192.	1.9	13
185	Ovarian cancer emerging subtypes: Role of oxidative stress and fibrosis in tumour development and response to treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1092-1098.	1.2	26
186	ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 121-131.	1.3	38
187	Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. <i>Gynecologic Oncology Case Reports</i> , 2013, 3, 7-10.	0.9	2
188	Nanocarriers for the targeted treatment of ovarian cancers. <i>Biomaterials</i> , 2013, 34, 1073-1101.	5.7	64
189	Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. <i>Annals of Oncology</i> , 2013, 24, 702-709.	0.6	64
190	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). <i>Gynecologic Oncology</i> , 2013, 130, 31-37.	0.6	20
192	Bevacizumab combined with low-dose S-1 as maintenance therapy with a long progression-free survival in an elderly patient with heavily pre-treated advanced gastric cancer: A case report. <i>Biomedical Reports</i> , 2013, 1, 239-242.	0.9	3
193	Morbidity of Surgery After Neoadjuvant Chemotherapy Including Bevacizumab for Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1326-1330.	1.2	18
194	Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells. <i>Cancer Biology and Therapy</i> , 2013, 14, 937-948.	1.5	11
195	Bevacizumab treatment and quality of life in advanced ovarian cancer. <i>Future Oncology</i> , 2013, 9, 951-954.	1.1	2

#	ARTICLE	IF	CITATIONS
196	Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. <i>Modern Pathology</i> , 2013, 26, 544-552.	2.9	13
197	Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation. <i>Molecular Therapy</i> , 2013, 21, 338-347.	3.7	63
198	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 874-889.	0.8	38
199	Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 296.	1.3	34
200	Targeting Signaling Pathways in Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 9536-9555.	1.8	51
201	Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target. <i>Frontiers in Oncology</i> , 2013, 3, 47.	1.3	24
202	Bevacizumab for the Treatment of Glioblastoma. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S8503.	0.6	64
203	Non-inferiority cancer clinical trials: scope and purposes underlying their design. <i>Annals of Oncology</i> , 2013, 24, 1942-1947.	0.6	27
204	New developments in the treatment of ovarian cancer—future perspectives. <i>Annals of Oncology</i> , 2013, 24, x69-x76.	0.6	42
205	The current state of pemetrexed in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1201-1210.	1.9	2
206	New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. <i>BioMed Research International</i> , 2013, 2013, 1-13.	0.9	22
207	Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-12.	2.5	48
208	Specialized Pathology Review in Patients With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1376-1382.	1.2	28
209	Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi24-vi32.	0.6	721
210	Ovarian Cancer: Sites of Recurrence. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1590-1596.	1.2	61
211	Angiogenesis as a target for the treatment of ovarian cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 558-565.	1.1	25
212	Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. <i>Clinical Cancer Research</i> , 2013, 19, 5227-5239.	3.2	63
213	Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. , 2013, , CD010482.		12

#	ARTICLE	IF	CITATIONS
214	Maintenance Chemotherapy for Advanced Non-Small-Cell Lung Cancer: New Life for an Old Idea. <i>Journal of Clinical Oncology</i> , 2013, 31, 1009-1020.	0.8	125
215	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2171-2182.	0.9	16
216	Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1219-1225.	1.2	18
217	Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents. <i>Frontiers in Oncology</i> , 2013, 3, 259.	1.3	65
218	Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (<sc>COSP</sc>) is a reliable high-throughput tool for case review. <i>Histopathology</i> , 2013, 63, 704-712.	1.6	5
219	Sorafenib for ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1049-1062.	1.9	18
220	Contemporary use of bevacizumab in ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 283-294.	1.4	14
221	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9845-9850.	3.3	176
222	A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma. <i>Molecular Therapy</i> , 2013, 21, 1456-1463.	3.7	88
223	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e22789.	2.1	92
224	Patients'™ and oncologists'™ views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. <i>British Journal of Cancer</i> , 2013, 108, 2264-2271.	2.9	29
225	Monoclonal antibodies therapies for ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 739-764.	1.4	21
226	Gastropleural Fistula in a Patient With Recurrent Ovarian Cancer Receiving Combination Therapy With Carboplatin, Gemcitabine, and Bevacizumab. <i>Journal of Clinical Oncology</i> , 2013, 31, e208-e210.	0.8	10
227	Anti-VEGF and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12018-12023.	3.3	110
228	Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2909-2916.	1.9	8
230	New Issues in Systemic Therapy for Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 690-693.	2.3	5
231	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 833-838.	1.2	7
232	European Society for Medical Oncology 2012 annual meeting: update on oncology trials. <i>Clinical Investigation</i> , 2013, 3, 17-19.	0.0	0

#	ARTICLE	IF	CITATIONS
233	Feasibility of Trials in Ovarian Cancer by Line of Therapy and Platinum Sensitivity. International Journal of Gynecological Cancer, 2013, 23, 481-487.	1.2	0
234	Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 355-360.	1.2	14
235	Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. Journal of Clinical Investigation, 2013, 123, 3190-3200.	3.9	527
236	Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. BMJ Case Reports, 2013, 2013, bcr2012007995-bcr2012007995.	0.2	15
237	Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. OncoTargets and Therapy, 2013, 6, 1197.	1.0	12
238	Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer. Journal of Gynecologic Oncology, 2013, 24, 209.	1.0	7
239	Current status of bevacizumab in advanced ovarian cancer. OncoTargets and Therapy, 2013, 6, 889.	1.0	11
240	Major clinical research advances in gynecologic cancer in 2012. Journal of Gynecologic Oncology, 2013, 24, 66.	1.0	36
241	Advanced ovarian cancer: what should be the standard of care?. Journal of Gynecologic Oncology, 2013, 24, 83.	1.0	40
242	Update on first-line treatment of advanced ovarian carcinoma. International Journal of Women's Health, 2013, 5, 45.	1.1	32
243	Conservative Management for an Entero-Adnexal Fistula at Initial Presentation of Advanced Ovarian Carcinoma. Current Oncology, 2013, 20, 44-47.	0.9	4
244	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 2013, 24, 359.	1.0	16
245	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clinical Pharmacology: Advances and Applications, 2013, 5, 13.	0.8	6
247	Should studies of maintenance therapy be maintained in women with ovarian cancer?. Journal of Gynecologic Oncology, 2013, 24, 105.	1.0	10
248	A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer. Journal of Gynecologic Oncology, 2013, 24, 154.	1.0	8
249	Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmacogenomics and Personalized Medicine, 2013, 6, 113.	0.4	16
250	Can We Maximize Both Value and Quality in Gynecologic Cancer Care? A Work in Progress. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e268-e275.	1.8	2
251	Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics. Critical Reviews in Oncogenesis, 2014, 19, 281-315.	0.2	37

#	ARTICLE	IF	CITATIONS
252	Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1273.	1.0	9
253	Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management. <i>International Journal of Women's Health</i> , 2014, 6, 149.	1.1	4
254	Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 1837.	1.0	7
255	Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. <i>International Journal of Women's Health</i> , 2014, 6, 289.	1.1	20
256	Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 1025.	1.0	10
257	Transforming the Future of Treatment for Ovarian Cancer. <i>Clinical & Experimental Pharmacology</i> , 2014, 04, .	0.3	0
258	Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity. <i>OncoTargets and Therapy</i> , 2014, 7, 469.	1.0	3
259	Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 751.	1.0	12
260	Epithelial ovarian cancer: An overview. <i>World Journal of Translational Medicine</i> , 2014, 3, 1.	3.5	109
261	Ovarian Cancer: Targeting the Untargetable. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 13-15.	1.8	3
262	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
263	Trial Watch. <i>OncoImmunology</i> , 2014, 3, e27048.	2.1	69
264	Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by Heparin-binding Epidermal Growth Factor (EGF)-like Growth Factor/EGF Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2014, 289, 10488-10501.	1.6	48
265	Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. <i>Systems Biology in Reproductive Medicine</i> , 2014, 60, 2-13.	1.0	13
266	Therapeutic targeting of tumor angiogenesis: how far have we come?. <i>Clinical Investigation</i> , 2014, 4, 1113-1122.	0.0	0
267	Role of mesenchymal cells in the natural history of ovarian cancer: a review. <i>Journal of Translational Medicine</i> , 2014, 12, 271.	1.8	23
269	MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. <i>BMC Cancer</i> , 2014, 14, 837.	1.1	52
270	Ovarian Cancer and Antiangiogenic Therapy: Caveat Emptor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3353-3356.	0.8	15

#	ARTICLE	IF	CITATIONS
272	SEOM guideline in ovarian cancer 2014. <i>Clinical and Translational Oncology</i> , 2014, 16, 1067-1071.	1.2	13
273	Anti-angiogenic Therapy Versus Dose-Dense Paclitaxel Therapy for Frontline Treatment of Epithelial Ovarian Cancer: Review of Phase III Randomized Clinical Trials. <i>Current Oncology Reports</i> , 2014, 16, 412.	1.8	4
274	The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1105-1113.	1.1	2
275	Molecular Basis for Targeted Therapy in Gynecologic Cancer. , 2014, , 1375-1383.		0
276	Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. <i>Carcinogenesis</i> , 2014, 35, 1951-1961.	1.3	55
277	Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report. <i>OncoTargets and Therapy</i> , 2014, 7, 165.	1.0	7
279	The Angiogenic Activity of Ascites in the Course of Ovarian Cancer as a Marker of Disease Progression. <i>Disease Markers</i> , 2014, 2014, 1-5.	0.6	14
280	The development of anti-angiogenic heparan sulfate oligosaccharides. <i>Biochemical Society Transactions</i> , 2014, 42, 1596-1600.	1.6	6
281	Potential Application of Curcumin and Its Analogues in the Treatment Strategy of Patients with Primary Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21703-21722.	1.8	70
282	The Role of MicroRNAs in Ovarian Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	132
283	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4549-4558.	3.2	63
284	A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. <i>Indian Journal of Cancer</i> , 2014, 51, 95.	0.2	8
285	New biological treatments for gynecological tumors: focus on angiogenesis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 337-346.	1.4	6
286	Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: A retrospective study of 37 cases. <i>Indian Journal of Cancer</i> , 2014, 51, 92.	0.2	3
287	Bevacizumab in the treatment of epithelial ovarian carcinoma. <i>Clinical Investigation</i> , 2014, 4, 535-548.	0.0	0
288	Metronomic Chemotherapy. , 2014, , .		3
289	Resistance to antiangiogenic therapies. <i>Future Oncology</i> , 2014, 10, 1417-1425.	1.1	10
290	Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1497-1505.	0.8	9

#	ARTICLE	IF	CITATIONS
291	Antitumor effects of bevacizumab in a microenvironmentâ€dependent human adult <sc>T</sc>â€cell leukemia/lymphoma mouse model. <i>European Journal of Haematology</i> , 2014, 92, 219-228.	1.1	6
292	The Wilms' Tumor Gene WT1 âˆ™ 17AA/âˆ™ KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model. <i>Translational Oncology</i> , 2014, 7, 580-589.	1.7	8
293	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 103-114.	1.4	6
294	Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2014, 93, 959-964.	1.3	45
295	Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review. <i>Materials Science and Engineering C</i> , 2014, 45, 609-619.	3.8	62
296	Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups. <i>Clinical Drug Investigation</i> , 2014, 34, 681-690.	1.1	35
297	Epithelial ovarian cancer - more data, more questions?. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 479-486.	0.5	13
298	Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment. <i>Oncology</i> , 2014, 87, 232-245.	0.9	13
299	Differential Therapeutic Effects of Antiâ€VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 202-213.	1.9	14
301	Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. <i>BMC Cancer</i> , 2014, 14, 696.	1.1	45
302	Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 16-22.	0.9	20
303	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancerâ€A Phase 1 Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 682-686.	1.2	16
304	High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 402-410.	0.9	45
305	Maintenance Therapy With Autologous Cytokine-induced Killer Cells in Patients With Advanced Epithelial Ovarian Cancer After First-line Treatment. <i>Journal of Immunotherapy</i> , 2014, 37, 115-122.	1.2	42
306	Taxanes in combination with biologic agents for ovarian and breast cancers. <i>Anti-Cancer Drugs</i> , 2014, 25, 536-554.	0.7	2
307	Phase II Clinical Trial of Oxaliplatin and Bevacizumab in Refractory Germ Cell Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 450-453.	0.6	24
308	Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Testâ€Retest Measurements for Tumor FDG Uptake, Diameter, and Volume. <i>Clinical Cancer Research</i> , 2014, 20, 2751-2760.	3.2	38
309	Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. <i>Nanomedicine</i> , 2014, 9, 501-522.	1.7	9

#	ARTICLE	IF	CITATIONS
310	Pegylated liposomal doxorubicin in the management of ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 707-720.	1.5	45
311	Recurrent Ovarian Cancer: When to Treat and How to Assess. , 2014, , 17-27.		0
312	Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. <i>Angiogenesis</i> , 2014, 17, 909-920.	3.7	40
314	Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3123-3136.	1.9	29
315	Cost Effectiveness and Cancer Drugs. <i>Journal of Clinical Oncology</i> , 2014, 32, 1091-1092.	0.8	4
316	Incidence and Relevance of Proteinuria in Bevacizumab-Treated Patients: Pooled Analysis from Randomized Controlled Trials. <i>American Journal of Nephrology</i> , 2014, 40, 75-83.	1.4	41
317	Maintenance therapy in ovarian cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 521-528.	1.1	23
318	Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. <i>Gynecologic Oncology</i> , 2014, 133, 467-472.	0.6	23
319	A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. <i>Gynecologic Oncology</i> , 2014, 132, 517-525.	0.6	22
320	Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2014, 53, 35-42.	0.5	4
321	Interleukin-6: An angiogenic target in solid tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 129-139.	2.0	112
322	Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2014, 133, 439-445.	0.6	35
323	A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 68.e1-68.e8.	0.7	17
324	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 133, 473-479.	0.6	53
325	Circulating and disseminated tumor cells in ovarian cancer: A systematic review. <i>Gynecologic Oncology</i> , 2014, 133, 632-639.	0.6	37
326	Dysphonia induced by anti-angiogenic compounds. <i>Investigational New Drugs</i> , 2014, 32, 774-782.	1.2	19
327	Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study. <i>Cancer</i> , 2014, 120, 335-343.	2.0	49
328	Advances in Diagnosis and Management of Ovarian Cancer. , 2014, , .		3

#	ARTICLE	IF	CITATIONS
329	Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 677-683.	0.6	32
330	Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for) Tj ETQq1 1 0,784314 rgBT /Ov	1.3	9
331	Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. <i>Gynecologic Oncology</i> , 2014, 132, 8-17.	0.6	65
332	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. <i>Angiogenesis</i> , 2014, 17, 471-494.	3.7	626
333	Genetic markers of bevacizumab-induced hypertension. <i>Angiogenesis</i> , 2014, 17, 685-94.	3.7	24
334	Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 361-369.	1.2	15
335	Novel therapies, including enzastaurin, in the treatment of ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 579-598.	1.9	6
336	Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 105-110.	0.6	23
337	A preoperative nomogram for decision making in oncological surgical emergencies. <i>Journal of Surgical Oncology</i> , 2014, 109, 721-725.	0.8	11
340	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	5.1	327
341	Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin. <i>Cancer Treatment Reviews</i> , 2014, 40, 366-375.	3.4	58
342	Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 207-216.	2.0	154
343	Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications. <i>Gynecologic Oncology</i> , 2014, 132, 496-505.	0.6	98
344	Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 17-39.	2.7	156
345	Bevacizumab: A Review of Its Use in Advanced Cancer. <i>Drugs</i> , 2014, 74, 1891-1925.	4.9	142
346	Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development: "When sweet turns sour". <i>Gynecologic Oncology</i> , 2014, 135, 371-381.	0.6	27
347	Metastasis review: from bench to bedside. <i>Tumor Biology</i> , 2014, 35, 8483-8523.	0.8	126
348	Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 293-304.	1.4	70

#	ARTICLE	IF	CITATIONS
349	Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. <i>Cell Death and Disease</i> , 2014, 5, e1510-e1510.	2.7	87
350	Cytoreductive Surgery for Advanced Ovarian Cancer. <i>Women's Health</i> , 2014, 10, 179-190.	0.7	12
351	A Systematic Review of Health State Utility Values for Advanced Ovarian Cancer. <i>Value in Health</i> , 2014, 17, A645.	0.1	4
352	SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. <i>European Journal of Cancer</i> , 2014, 50, 2939-2949.	1.3	108
353	Bevacizumab in Treatment of High-Risk Ovarian Cancer—A Cost-Effectiveness Analysis. <i>Oncologist</i> , 2014, 19, 523-527.	1.9	33
354	Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1210-1217.	0.8	77
356	Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II–IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). <i>Annals of Oncology</i> , 2014, 25, 251-257.	0.6	28
357	Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2014, 50, 2592-2601.	1.3	33
358	The multifaceted activity of VEGF in angiogenesis—Implications for therapy responses. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 473-482.	3.2	120
360	Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , 2014, 50, 2611-2618.	1.3	50
361	Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1287-1289.	0.8	11
362	A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. <i>European Journal of Cancer</i> , 2014, 50, 2408-2416.	1.3	21
363	AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 325-332.	0.6	28
364	Combining targeted therapies in ovarian cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1179-1181.	5.1	3
365	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	7.7	252
366	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 799-808.	5.1	279
367	VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs. <i>Nature Reviews Endocrinology</i> , 2014, 10, 530-539.	4.3	89
368	The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 349-358.	0.6	25

#	ARTICLE	IF	CITATIONS
369	Biological Activity of Resveratrol on an Ovarian Cancer Cell. , 2014, , 1257-1268.		0
370	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1041-1050.	1.1	4
371	Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. <i>Experimental and Molecular Pathology</i> , 2014, 97, 298-304.	0.9	60
372	Overview of a chemoresponse assay in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 761-769.	1.2	26
373	Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 72.	1.3	12
374	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 883-893.	1.5	16
375	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3374-3382.	0.8	302
379	Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 893-906.	0.8	49
381	Une nouvelle place pour le bÃ©vacizumab : le cancer du col de lâ€™utÃ©rus avancÃ©. <i>Oncologie</i> , 2014, 16, 338-339.	0.2	0
382	Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. <i>Investigational New Drugs</i> , 2014, 32, 729-738.	1.2	27
383	Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 37-53.	1.9	15
384	Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. <i>Journal of Ovarian Research</i> , 2014, 7, 57.	1.3	52
385	Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). <i>Annals of Surgical Oncology</i> , 2014, 21, 2517-2524.	0.7	23
386	Monoclonal antibodies as therapeutics in human malignancies. <i>Future Oncology</i> , 2014, 10, 609-636.	1.1	20
387	New perspectives in ovarian cancer treatment. <i>Maturitas</i> , 2014, 77, 128-136.	1.0	53
388	The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. <i>Tumor Biology</i> , 2014, 35, 7675-7683.	0.8	10
389	First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions. <i>Drugs</i> , 2014, 74, 879-889.	4.9	20
390	Trebananib: an alternative anti-angiogenic strategy. <i>Lancet Oncology</i> , The, 2014, 15, 776-777.	5.1	2

#	ARTICLE	IF	CITATIONS
391	How I treat ovarian cancer in older women. <i>Journal of Geriatric Oncology</i> , 2014, 5, 223-229.	0.5	10
392	Breast and Ovarian Cancer in the Older Woman. <i>Journal of Clinical Oncology</i> , 2014, 32, 2553-2561.	0.8	70
393	Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster. , 2014, 141, 117-124.		41
394	Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1302-1308.	0.8	1,240
396	MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 568-574.	0.6	66
397	Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. <i>European Journal of Cancer</i> , 2014, 50, 1638-1648.	1.3	29
399	Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 537-541.	0.6	32
400	Sohlh2 inhibits ovarian cancer cell proliferation by upregulation of p21 and downregulation of cyclin D1. <i>Carcinogenesis</i> , 2014, 35, 1863-1871.	1.3	29
401	Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review. <i>Gynecologic Oncology</i> , 2014, 133, 147-154.	0.6	88
402	Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 555-560.	1.0	4
403	VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2. <i>Neoplasia</i> , 2014, 16, 343-353.e2.	2.3	95
404	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. <i>Gynecologic Oncology</i> , 2014, 134, 274-280.	0.6	58
405	Ovarian cancer. <i>Lancet</i> , The, 2014, 384, 1376-1388.	6.3	1,491
407	The emerging role of anti-angiogenic therapy in ovarian cancer. <i>International Journal of Oncology</i> , 2014, 44, 1417-1424.	1.4	18
409	New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances. <i>Clinical Cancer Research</i> , 2014, 20, 5150-5156.	3.2	108
410	Discordance between the results and conclusions of ICON7. <i>Lancet Oncology</i> , The, 2015, 16, e478.	5.1	2
411	Prognostic Significance of the Number of Postoperative Intraperitoneal Chemotherapy Cycles for Patients With Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 599-606.	1.2	13
412	Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. <i>Cancer Medicine</i> , 2015, 4, 673-681.	1.3	53

#	ARTICLE	IF	CITATIONS
413	Frontline treatment of epithelial ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 1-16.	0.7	12
415	Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling. <i>Scientific Reports</i> , 2015, 4, 4984.	1.6	8
416	The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival. <i>International Journal of Oncology</i> , 2015, 47, 2057-2063.	1.4	18
417	Ovarian cancer standard of care: are there real alternatives?. <i>Chinese Journal of Cancer</i> , 2015, 34, 17-27.	4.9	79
418	Low-grade epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 412-419.	1.1	21
420	Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 146.	1.8	95
421	Discordance between the results and conclusions of ICON7 – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e478-e479.	5.1	1
422	Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression. <i>Cancer Cell International</i> , 2015, 15, 52.	1.8	41
423	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. , 2015, 3, 52.		22
424	Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data. <i>Statistics in Medicine</i> , 2015, 34, 2881-2898.	0.8	51
425	The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1139-1148.	1.1	6
426	Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1855-1861.	2.8	21
427	Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1121.	0.4	11
428	Chemotherapy for Patients with <i>BRCA1</i> and <i>BRCA2</i> Mutated Ovarian Cancer: Same or Different?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 114-121.	1.8	45
429	Epithelial Ovarian Cancer in Older Women: Defining the Best Management Approach. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e311-e321.	1.8	4
430	Role of NSC319726 in ovarian cancer based on the bioinformatics analyses. <i>OncoTargets and Therapy</i> , 2015, 8, 3757.	1.0	5
431	Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 615.	0.7	6
432	Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France. <i>Clinical Epidemiology</i> , 2015, 7, 431.	1.5	2

#	ARTICLE	IF	CITATIONS
433	A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report. <i>OncoTargets and Therapy</i> , 2015, 8, 2097.	1.0	0
434	Have We Given up on a Cure for Ovarian Cancer?. <i>Current Oncology</i> , 2015, 22, 139-141.	0.9	3
435	Mesotelioma pleurico maligno: revisione ed analisi degli studi clinici presentati all'ASCO 2015. Working Paper of Public Health, 2015, 4, .	0.0	0
436	Therapeutic Innovations in Ovarian Cancer Treatment: The New England Perspective. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 2015, 05, .	0.1	0
437	El c�ncer ginecol�gico. <i>Arbor</i> , 2015, 191, a237.	0.1	1
438	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 211.	1.3	16
439	Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge. <i>Frontiers in Oncology</i> , 2015, 5, 229.	1.3	18
440	Critical appraisal of bevacizumab in the treatment of ovarian cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2351.	2.0	25
441	Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft. <i>PLoS ONE</i> , 2015, 10, e0126867.	1.1	24
442	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136324.	1.1	25
444	Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2015, 386, 249-257.	6.3	1,042
445	Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. <i>Clinical and Translational Oncology</i> , 2015, 17, 673-683.	1.2	21
446	Neoadjuvant and Adjuvant Chemotherapy for Advanced Ovarian Cancer, Including Biological Agents. , 2015, , 441-453.		0
447	Comparative Effectiveness Research in Gynecologic Oncology. <i>Cancer Treatment and Research</i> , 2015, 164, 237-259.	0.2	0
448	New perspectives on targeted therapy in ovarian cancer. <i>International Journal of Women's Health</i> , 2015, 7, 189.	1.1	93
449	Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. <i>Translational Oncology</i> , 2015, 8, 424-433.	1.7	27
450	Tratamiento m�dico del c�ncer epitelial de ovario. <i>EMC - Ginecolog�a-Obstetricia</i> , 2015, 51, 1-5.	0.0	0
451	Inhibitors of Angiogenesis. , 2015, , 261-285.		1

#	ARTICLE	IF	CITATIONS
452	Protein Targeting Compounds. , 2015, , .		1
453	Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. <i>BMC Systems Biology</i> , 2015, 9, 55.	3.0	20
454	Targeted therapy in gynecologic cancers: Ready for prime time?. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S150-2.	1.0	5
455	Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 302-308.	0.9	6
456	Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?. <i>Gynecologic Oncology</i> , 2015, 136, 43-47.	0.6	24
457	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology</i> , The, 2015, 16, e43-e52.	5.1	72
458	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015, 136, 37-42.	0.6	29
459	Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. <i>Gynecologic Oncology</i> , 2015, 136, 121-129.	0.6	12
460	Bevacizumab: A dose review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 311-322.	2.0	32
461	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
462	The 21st Century Handbook of Clinical Ovarian Cancer. , 2015, , .		6
463	A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 136, 293-299.	0.6	24
464	Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy. <i>Cancer Treatment Reviews</i> , 2015, 41, 136-143.	3.4	76
465	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. <i>Oncologist</i> , 2015, 20, 166-175.	1.9	66
466	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-148.	0.8	113
467	IKK β Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 909-919.	1.9	22
468	Influence of vascular normalization on interstitial flow and delivery of liposomes in tumors. <i>Physics in Medicine and Biology</i> , 2015, 60, 1477-1496.	1.6	16
469	Maintenance chemotherapy in the management of epithelial ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 11-17.	2.7	22

#	ARTICLE	IF	CITATIONS
470	New Insights into Antimetastatic and Antiangiogenic Effects of Cannabinoids. <i>International Review of Cell and Molecular Biology</i> , 2015, 314, 43-116.	1.6	15
471	Angiogenesis in primary hyperparathyroidism. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 91-98.	0.6	6
472	Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. <i>Molecular Cancer Research</i> , 2015, 13, 795-806.	1.5	25
473	MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an 18F labeled RGD-based probe in SKOV-3 xenograft-bearing mice. <i>Tumor Biology</i> , 2015, 36, 3285-3291.	0.8	9
474	CXCR7 signaling induced epithelialâ€mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas. <i>Tumor Biology</i> , 2015, 36, 1679-1683.	0.8	22
476	Optimal follow-up of ovarian cancer patients. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 57-61.	0.3	0
477	AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4418-27.	3.3	45
478	Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2015, 138, 201-206.	0.6	52
479	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 323-336.	2.0	24
480	Immunology and Immunotherapy of Ovarian Cancer. , 2015, , 413-456.		1
481	A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia. <i>Gynecologic Oncology</i> , 2015, 138, 55-61.	0.6	62
482	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , 2015, 112, 1326-1331.	2.9	30
483	Cisplatin-, Doxorubicin-, and Docetaxel-Induced Cell Death Promoted by the Aqueous Extract of <i>Solanum nigrum</i> in Human Ovarian Carcinoma Cells. <i>Integrative Cancer Therapies</i> , 2015, 14, 546-555.	0.8	27
484	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 928-936.	5.1	661
485	Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 139, 413-418.	0.6	18
487	Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 113-128.	2.0	28
488	Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. <i>Pharmacoeconomics</i> , 2015, 33, 1155-1185.	1.7	16
489	Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. <i>International Immunology</i> , 2015, 27, 621-632.	1.8	30

#	ARTICLE	IF	CITATIONS
490	Oxaliplatin for the treatment of ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1275-1286.	1.9	23
491	Current and Future Therapies for Advanced Gastric Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 239-250.	1.0	28
492	Targeted survival improvements in clinical trials: Are you an absolutist or relativist?. <i>Cancer</i> , 2015, 121, 335-338.	2.0	2
493	Host effects contributing to cancer therapy resistance. <i>Drug Resistance Updates</i> , 2015, 19, 33-42.	6.5	38
494	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 561-568.	5.1	141
495	A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. <i>Gynecologic Oncology</i> , 2015, 137, 490-496.	0.6	52
496	Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 579-594.	1.1	17
497	Targeting the microenvironment in ovarian cancer. <i>Lancet Oncology, The</i> , 2015, 16, 485-486.	5.1	2
498	Towards risk-adapted therapy for rhabdoid tumour subgroups. <i>Lancet Oncology, The</i> , 2015, 16, 486-488.	5.1	4
499	Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 645-651.	1.1	8
500	The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 1381-1386.	0.8	5
501	Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. <i>Supportive Care in Cancer</i> , 2015, 23, 1827-1835.	1.0	34
503	Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers. <i>Current Treatment Options in Oncology</i> , 2015, 16, 318.	1.3	21
504	Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 345-362.	1.9	1
505	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 656-666.	5.1	114
506	Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial). <i>Clinical Cancer Research</i> , 2015, 21, 5253-5263.	3.2	9
507	Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 582-589.	1.0	11
508	Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. <i>Future Oncology</i> , 2015, 11, 909-922.	1.1	15

#	ARTICLE	IF	CITATIONS
509	Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386). <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 302-310.	2.0	16
510	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	1.5	22
511	Oxaliplatin Is a Safe Alternative Option for Patients With Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 42-48.	1.2	17
512	Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3970-3975.	0.7	64
513	Breaking Down the Evidence for Bevacizumab in Ovarian Cancer. <i>Oncologist</i> , 2015, 20, 91-93.	1.9	3
514	Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 408-410.	0.6	17
515	Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. <i>Gynecologic Oncology</i> , 2015, 137, 392-400.	0.6	14
516	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 647-658.	1.7	17
517	Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 309, C444-C456.	2.1	272
518	Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 952-958.	0.7	51
519	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S111-22.	1.0	70
520	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
521	An overview of early investigational therapies for chemoresistant ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1163-1183.	1.9	15
522	Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. <i>Annals of Oncology</i> , 2015, 26, 2034-2043.	0.6	241
523	Ovarian cancer treatment: The end of empiricism?. <i>Cancer</i> , 2015, 121, 3203-3211.	2.0	30
524	The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis. <i>Journal of Ovarian Research</i> , 2015, 8, 54.	1.3	12
525	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
526	Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 10-16.	0.6	259

#	ARTICLE	IF	CITATIONS
527	State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 223-226.	0.6	33
528	Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2015, 139, 17-22.	0.6	74
529	Pazopanib in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 995-1005.	1.1	14
530	The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer. <i>Women's Health</i> , 2015, 11, 355-367.	0.7	8
531	Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes—The Example of Bevacizumab in Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1539-1542.	0.8	5
532	Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 23-29.	0.6	27
533	Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. <i>Gynecologic Oncology</i> , 2015, 138, 278-284.	0.6	19
534	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2015, 139, 59-62.	0.6	45
535	A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR- $\hat{1}^2$, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. <i>Investigational New Drugs</i> , 2015, 33, 1217-1224.	1.2	14
536	Molecular Pathogenesis of Ovarian Cancer. , 2015, , 531-548.e2.		2
537	A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity — CLEOPATRA and PENELOPE. <i>Future Oncology</i> , 2015, 11, 3113-3131.	1.1	17
538	Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. <i>Future Oncology</i> , 2015, 11, 3167-3174.	1.1	9
539	Bevacizumab in newly diagnosed ovarian cancer. <i>Lancet Oncology</i> , The, 2015, 16, 876-878.	5.1	8
540	<scp>MiR</scp>â€506 inhibits multiple targets in the epithelialâ€toâ€mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. <i>Journal of Pathology</i> , 2015, 235, 25-36.	2.1	94
541	Dose-dense Paclitaxel in Advanced Ovarian Cancer. <i>Clinical Oncology</i> , 2015, 27, 40-47.	0.6	25
542	Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 613-634.	2.4	2
543	Immune Effects of Bevacizumab: Killing Two Birds with One Stone. <i>Cancer Microenvironment</i> , 2015, 8, 15-21.	3.1	49
544	Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. <i>Cancer</i> , 2015, 121, 413-422.	2.0	3

#	ARTICLE	IF	CITATIONS
545	Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials. <i>Cancer</i> , 2015, 121, 1737-1746.	2.0	59
546	<i>Gynecologic Oncology</i> , 2015, , .		2
547	Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 843-849.	1.1	38
548	Crk-like adapter protein is required for TGF- β -induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas. <i>Tumor Biology</i> , 2015, 36, 915-919.	0.8	10
549	Recurrent Ovarian Cancer – Basic Knowledge, Current Management, and Future Directions. , 0, , .		0
550	Cardiovascular Toxicity of Bevacizumab in Long-term Survival of Recurrent Ovarian Cancer: A Case Report. <i>Cancer and Clinical Oncology</i> , 2016, 5, 1.	0.2	0
551	Ovarian Cancer Research in the Post Genomic Era – Challenges and Opportunities. , 0, , .		0
552	Analysing Molecular Mechanism Related to Therapy-Resistance in In-vitro Models of Ovarian Cancer. , 2016, , .		0
553	The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada. <i>Current Oncology</i> , 2016, 23, 461-467.	0.9	7
554	Targeted therapy and immunotherapy in ovarian cancer. <i>Journal of the Korean Medical Association</i> , 2016, 59, 180.	0.1	1
555	Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2016, 9, 2421.	1.0	13
556	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. <i>Current Cancer Therapy Reviews</i> , 2016, 12, 23-36.	0.2	0
557	Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-oesophageal junction adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4539-4548.	1.0	3
558	Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. <i>Ecanermedicalscience</i> , 2016, 10, 626.	0.6	33
559	Nicosamide and its analogs are potent inhibitors of Wnt/ β -catenin, mTOR and STAT3 signaling in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 86803-86815.	0.8	64
560	Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?. <i>Journal of Oncology Practice</i> , 2016, 12, e775-e783.	2.5	8
561	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2113.	1.8	165
562	Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. <i>Frontiers in Oncology</i> , 2016, 6, 244.	1.3	15

#	ARTICLE	IF	CITATIONS
563	Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. <i>Biomolecules</i> , 2016, 6, 3.	1.8	43
564	Major clinical research advances in gynecologic cancer in 2015. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e53.	1.0	20
565	Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. <i>International Journal of Women's Health</i> , 2016, 8, 59.	1.1	27
566	The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 231-238.	0.6	12
567	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016, 115, 228-235.	2.9	23
568	Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO). <i>Annals of Oncology</i> , 2016, 27, 1740-1746.	0.6	11
569	Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain. <i>Medicine (United States)</i> , 2016, 95, 1074-1081.	0.24	7
570	The role of cediranib in ovarian cancer: current status and further investigation. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 855-865.	0.5	0
571	Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients. <i>Oncology Letters</i> , 2016, 12, 680-686.	0.8	15
573	Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. <i>BMC Cancer</i> , 2016, 16, 473.	1.1	5
574	Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. <i>ESMO Open</i> , 2016, 1, e000039.	2.0	27
575	TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer. <i>Oncology Reports</i> , 2016, 35, 359-365.	1.2	9
577	Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. <i>BMC Medical Imaging</i> , 2016, 16, 52.	1.4	6
578	Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study. <i>Gynecologic Oncology</i> , 2016, 142, 231-236.	0.6	16
580	Targeted Therapy in Ovarian Cancer. <i>Women's Health</i> , 2016, 12, 363-378.	0.7	28
581	Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 142, 25-29.	0.6	16
582	VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. <i>Clinical Cancer Research</i> , 2016, 22, 4249-4258.	3.2	28
583	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 387, 1066-1074.	6.3	216

#	ARTICLE	IF	CITATIONS
584	Mucinous ovarian cancer: A therapeutic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 26-36.	2.0	38
585	Molecular imaging in ovarian cancer. <i>Annals of Oncology</i> , 2016, 27, i23-i29.	0.6	5
586	The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. <i>Reproductive Sciences</i> , 2016, 23, 1484-1492.	1.1	15
587	Mucinous epithelial ovarian carcinoma. <i>Annals of Oncology</i> , 2016, 27, i53-i57.	0.6	84
588	Anti-angiogenic agents in ovarian cancer: past, present, and future. <i>Annals of Oncology</i> , 2016, 27, i33-i39.	0.6	115
589	The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. <i>Developmental Cell</i> , 2016, 37, 114-125.	3.1	96
590	Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 611-626.	12.5	103
591	Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). <i>Annals of Oncology</i> , 2016, 27, 1006-1013.	0.6	7
592	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. <i>Value in Health</i> , 2016, 19, 431-439.	0.1	20
593	Clinical relevance of circulating cell-free microRNAs in ovarian cancer. <i>Molecular Cancer</i> , 2016, 15, 48.	7.9	149
594	In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors". <i>Journal of Oncology Practice</i> , 2016, 12, 273-274.	2.5	4
595	Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2016, 28, 760-765.	0.6	7
597	Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 143, 504-510.	0.6	77
598	Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?. <i>Gynecologic Oncology Reports</i> , 2016, 17, 65-68.	0.3	19
599	Therapeutic targets and new directions for antibodies developed for ovarian cancer. <i>MAbs</i> , 2016, 8, 1437-1455.	2.6	15
600	Comparison of prognoses according to non- β -positive and positive spectrin β II expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.. <i>Cancer Medicine</i> , 2016, 5, 1081-1092.	1.3	2
601	Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2016, 139, 2850-2858.	2.3	54
602	CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Research</i> , 2016, 76, 6118-6129.	0.4	145

#	ARTICLE	IF	CITATIONS
603	Developmental Therapeutics for Gynecologic Cancers: An Overview. , 2016, , 99-125.		0
604	First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies. <i>Oncologist</i> , 2016, 21, 1286-1290.	1.9	2
605	Does clinical trial participation improve outcomes in patients with ovarian cancer?. <i>ESMO Open</i> , 2016, 1, e000057.	2.0	9
606	Improving outcomes for older women with gynaecological malignancies. <i>Cancer Treatment Reviews</i> , 2016, 50, 99-108.	3.4	39
607	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	0.6	81
608	Advances in Ovarian Cancer and Ongoing Clinical Trials. , 2016, , 65-77.		0
609	Update on chemotherapy in gynaecological cancers. <i>The Obstetrician and Gynaecologist</i> , 2016, 18, 182-188.	0.2	8
610	Gynecological Cancers. , 2016, , .		0
611	Applying quantitative adiposity feature analysis models to predict benefit of bevacizumab-based chemotherapy in ovarian cancer patients. <i>Proceedings of SPIE</i> , 2016, , .	0.8	0
612	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , 2016, 69, 199-215.	1.3	34
613	The Clinical Relevance of Beta Blockers in Ovarian Carcinoma. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 1050-1056.	0.8	9
614	Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. <i>Chinese Journal of Cancer</i> , 2016, 35, 61.	4.9	32
615	Precision targeted therapy of ovarian cancer. <i>Journal of Controlled Release</i> , 2016, 243, 250-268.	4.8	59
616	Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. <i>Nature Communications</i> , 2016, 7, 12680.	5.8	89
617	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16061.	18.1	761
618	Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. <i>Gynecologic Oncology</i> , 2016, 143, 622-627.	0.6	19
619	A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. <i>Scientific Reports</i> , 2016, 6, 31079.	1.6	18
620	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	5.8	100

#	ARTICLE	IF	CITATIONS
621	What Is the Clinical Value Associated with Defining Additional Disease-Specific "Prognostic Indicators"? <i>Oncology</i> , 2016, 90, 57-58.	0.9	0
622	Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma. <i>EJNMMI Research</i> , 2016, 6, 42.	1.1	5
623	Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. , 2016, 4, 34.		34
624	Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab. <i>Medicine (United States)</i> , 2016, 95, e4232.	0.4	16
625	Prediction of chemo-response in serous ovarian cancer. <i>Molecular Cancer</i> , 2016, 15, 66.	7.9	33
627	A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1196-1200.	1.2	7
628	Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy. <i>Case Reports in Oncology</i> , 2016, 9, 195-204.	0.3	8
629	Brief "exposure to preoperative bevacizumab reveals a TGF" signature predictive of response in HER2"negative breast cancers. <i>International Journal of Cancer</i> , 2016, 138, 747-757.	2.3	16
630	Understanding the value of cancer drugs"the devil is in the detail. <i>Cancer</i> , 2016, 122, 2292-2295.	2.0	4
631	Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?. <i>Molecular Cancer</i> , 2016, 15, 13.	7.9	46
632	Future options of anti-angiogenic cancer therapy. <i>Chinese Journal of Cancer</i> , 2016, 35, 21.	4.9	42
633	Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies. <i>Current Oncology Reports</i> , 2016, 18, 44.	1.8	25
634	The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors. <i>Microvascular Research</i> , 2016, 107, 91-96.	1.1	10
635	FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. <i>Gynecologic Oncology</i> , 2016, 142, 597-607.	0.6	64
636	Inhibitors of Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2016, 917, 261-285.	0.8	2
638	Monitoring vascular normalization induced by antiangiogenic treatment with 18F"fluoromisonidazole"PET. <i>Molecular Oncology</i> , 2016, 10, 704-718.	2.1	36
639	Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. <i>BMC Medical Research Methodology</i> , 2016, 16, 16.	1.4	51
640	Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 237-242.	0.6	45

#	ARTICLE	IF	CITATIONS
641	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1733-1739.	0.6	28
642	Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 771-776.	0.5	5
643	Cediranib in ovarian cancer: state of the art and future perspectives. <i>Tumor Biology</i> , 2016, 37, 2833-2839.	0.8	16
644	Can advanced-stage ovarian cancer be cured?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 255-261.	12.5	292
645	Prediction of anti-angiogenesis escape. <i>Gynecologic Oncology</i> , 2016, 141, 80-85.	0.6	15
646	Jump in the fire – heat shock proteins and their impact on ovarian cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 152-156.	2.0	15
647	The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II. <i>International Journal of Oncology</i> , 2016, 48, 998-1006.	1.4	18
648	Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1659-1671.	1.2	25
649	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	5.1	205
651	Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models. <i>Cancer Gene Therapy</i> , 2016, 23, 24-28.	2.2	23
652	The Novel $\text{I}\kappa\text{B}$ Kinase $\text{I}\kappa\text{B}$ Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 610-618.	1.2	1
653	Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF- κB pathway. <i>Tumor Biology</i> , 2016, 37, 11469-11477.	0.8	25
654	Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. <i>Gynecologic Oncology</i> , 2016, 141, 65-71.	0.6	11
655	Targeting metastasis. <i>Nature Reviews Cancer</i> , 2016, 16, 201-218.	12.8	1,111
656	Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>European Journal of Cancer</i> , 2016, 59, 22-33.	1.3	297
657	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 600-611.	5.1	43
658	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. <i>Gynecologic Oncology</i> , 2016, 140, 443-449.	0.6	47
659	Targeting the tumour microenvironment in ovarian cancer. <i>European Journal of Cancer</i> , 2016, 56, 131-143.	1.3	84

#	ARTICLE	IF	CITATIONS
660	Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. <i>Journal of Controlled Release</i> , 2016, 226, 148-167.	4.8	42
661	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , 2016, 388, 518-529.	6.3	663
662	The Role of the Immune System in Ovarian Cancer and Implications on Therapy. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 681-695.	1.3	5
663	Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 437-442.	1.2	11
664	Olaparib for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 995-1003.	0.9	12
665	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 738-748.	13.9	303
666	Current and emerging treatment options in the management of advanced ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1063-1076.	0.9	8
667	Targeted agents and combinations in ovarian cancer: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 441-454.	1.1	12
668	Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2016, 32, 555-562.	0.9	17
669	Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 706-713.	0.8	60
670	Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials. <i>Tumor Biology</i> , 2016, 37, 6297-6306.	0.8	0
671	Integrated care in ovarian cancer <i>ÖlgV Ovar</i> results of a German pilot for higher quality in treatment of ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 481-487.	1.2	8
672	Ovarian Cancer in Elderly Patients. , 2016, , .		1
673	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 31-49.	1.9	35
674	Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 180-188.	2.0	39
675	Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 421-427.	0.8	8
677	Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 335-348.	2.0	22
678	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 125-135.	1.9	56

#	ARTICLE	IF	CITATIONS
679	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 7-15.	1.0	3
680	The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas. <i>Tumor Biology</i> , 2016, 37, 823-828.	0.8	13
681	Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. <i>Clinical and Translational Oncology</i> , 2016, 18, 40-46.	1.2	13
682	Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. <i>Pharmacogenomics Journal</i> , 2016, 16, 243-248.	0.9	10
683	Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer. <i>Breast Cancer</i> , 2017, 24, 147-151.	1.3	4
684	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 9.	0.5	18
685	An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Practice, 2017, 23, 454-469.	0.5	9
686	Individualized Medicine in Ovarian Cancer: Are We There Yet?. <i>Gynecologic Oncology</i> , 2017, 144, 229-231.	0.6	0
687	Genomic insights in gynecologic cancer. <i>Current Problems in Cancer</i> , 2017, 41, 8-36.	1.0	13
688	Internationally Comparable Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2017, 29, 151-152.	0.6	0
689	Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach. <i>Pharmaceutical Research</i> , 2017, 34, 696-703.	1.7	20
690	Sizing clinical trials when comparing bivariate time-to-event outcomes. <i>Statistics in Medicine</i> , 2017, 36, 1363-1382.	0.8	12
691	Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 32-36.	0.6	7
692	Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. <i>Gynecologic Oncology</i> , 2017, 145, 37-40.	0.6	51
693	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	1.0	125
694	Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. <i>Annals of Medicine</i> , 2017, 49, 435-447.	1.5	61
695	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017, 75, 245-258.	1.3	82
696	The development and use of vascular targeted therapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 393-406.	0.6	68

#	ARTICLE	IF	CITATIONS
697	Optimal primary management of bulky stage IIIc ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
698	<scp>VEGFA</scp> activates an epigenetic pathway upregulating ovarian cancer-initiating cells. <i>EMBO Molecular Medicine</i> , 2017, 9, 304-318.	3.3	63
699	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	3.2	103
701	CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. <i>Clinical Cancer Research</i> , 2017, 23, 3684-3691.	3.2	20
703	Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer. <i>Medical Oncology</i> , 2017, 34, 87.	1.2	9
704	Immunotherapy and epithelial ovarian cancer: a double-edged sword?. <i>Annals of Oncology</i> , 2017, 28, 909-910.	0.6	4
706	PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 153-165.	2.0	37
707	Bevacizumab and paclitaxel+carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRC Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 779-791.	5.1	460
708	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 123-139.	0.5	64
709	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. <i>Annals of Oncology</i> , 2017, 28, 711-717.	0.6	125
710	Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017, 28, 1842-1848.	0.6	43
711	Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. <i>Annals of Oncology</i> , 2017, 28, 1817-1824.	0.6	36
712	Prediction of therapy response in ovarian cancer: Where are we now?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 233-266.	2.7	28
713	A brief review of the management of platinum-resistant+platinum-refractory ovarian cancer. <i>Medical Oncology</i> , 2017, 34, 103.	1.2	125
714	Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 314-322.	1.5	49
715	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	1.3	70
716	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. <i>European Journal of Cancer</i> , 2017, 70, 133-142.	1.3	86
717	Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: COG-0218 Biomarker Analyses. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	74

#	ARTICLE	IF	CITATIONS
718	Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 879-886.	1.2	15
719	The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 813-818.	1.2	0
720	Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 28-36.	1.2	31
721	Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab. <i>Targeted Oncology</i> , 2017, 12, 495-503.	1.7	14
722	Management of advanced ovarian cancer in South West Wales âˆ” a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort. <i>Cancer Epidemiology</i> , 2017, 49, 85-91.	0.8	2
723	Pathogenesis and heterogeneity of ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 26-34.	0.9	223
724	Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1325-1332.	1.2	22
725	Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5226-E5235.	3.3	28
726	Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. <i>Molecular Cancer</i> , 2017, 16, 97.	7.9	15
727	Precision Medicine in Gynecology and Obstetrics. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , .	0.0	1
728	Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 494-498.	0.6	8
729	Quality of life with cediranib in relapsed ovarian cancer: The <sc>ICON</sc>6 phase 3 randomized clinical trial. <i>Cancer</i> , 2017, 123, 2752-2761.	2.0	24
730	Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. <i>Scientific Reports</i> , 2017, 7, 45954.	1.6	29
731	Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. <i>Annals of Oncology</i> , 2017, 28, 920-921.	0.6	1
732	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
733	Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. <i>European Journal of Cancer</i> , 2017, 76, 52-59.	1.3	10
734	Targeted Therapies for Ovarian Cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 139-152.	1.4	95
735	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 53, 120-127.	3.4	178

#	ARTICLE	IF	CITATIONS
736	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. <i>Gynecologic Oncology</i> , 2017, 144, 256-259.	0.6	38
737	Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 509-513.	0.6	32
738	Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. <i>Annals of Oncology</i> , 2017, 28, 2733-2740.	0.6	52
739	Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. <i>Cancer Science</i> , 2017, 108, 2213-2220.	1.7	22
740	Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients. <i>Drugs and Aging</i> , 2017, 34, 821-831.	1.3	4
742	Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 6759-6769.	0.4	4
743	Manual of Cardio-oncology. , 2017, , .		1
744	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
745	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , 2017, 28, 2340-2366.	0.6	451
746	Bevacizumab in advanced lung cancer: state of the art. <i>Future Oncology</i> , 2017, 13, 2515-2535.	1.1	53
747	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. <i>Clinical Cancer Research</i> , 2017, 23, 7034-7046.	3.2	71
748	Cannabinoids as Anticancer Drugs. <i>Advances in Pharmacology</i> , 2017, 80, 397-436.	1.2	58
749	The role of Cediranib in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1637-1648.	0.9	31
750	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
751	Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20,000 Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	125
752	Nintedanib in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1073-1081.	1.9	19
753	A step towards the harmonization of clinical trials inform consent forms. <i>Annals of Oncology</i> , 2017, 28, 910-912.	0.6	0
756	Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2017, 56, 302-305.	0.5	11

#	ARTICLE	IF	CITATIONS
757	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
758	The anti-cancer effects of itraconazole in epithelial ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 6552.	1.6	37
759	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	2.0	4
760	Proper oral hygiene protocols decreased inflammation of gingivitis in a patient during chemotherapy with bevacizumab: a case report. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1352-1357.	0.2	2
761	Multi-omic parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 214-224.	1.3	8
762	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 41-46.	0.6	17
763	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 50-58.	1.2	61
764	Correlation of Collagen Triple Helix Repeat Containing 1 Overexpression With Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 22-27.	1.2	2
765	Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	8
766	Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer. <i>Oncology Reports</i> , 2017, 38, 3297-3308.	1.2	20
767	Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1205-1215.	1.5	1
768	Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 912-920.	0.4	13
769	Ovarian cancer: Novel molecular aspects for clinical assessment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 12-29.	2.0	25
770	Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 29.	6.9	39
772	Ovarian Cancers. , 2017, , .		1
773	Immunotherapy in ovarian cancer. <i>Current Problems in Cancer</i> , 2017, 41, 48-63.	1.0	27
774	A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 39-46.	0.6	21
775	Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. <i>Chemotherapy</i> , 2017, 62, 111-120.	0.8	33

#	ARTICLE	IF	CITATIONS
776	Luteal Angiogenesis. , 2017, , 1-21.		2
777	Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance. International Journal of Clinical Oncology, 2017, 22, 107-117.	1.0	14
778	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research, 2017, 23, 1862-1874.	3.2	107
779	Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecologic Oncology, 2017, 144, 181-186.	0.6	22
780	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 126-138.	1.4	32
781	How can molecular abnormalities influence our clinical approach. Annals of Oncology, 2017, 28, viii16-viii24.	0.6	37
782	Treatment of recurrent ovarian cancer. Annals of Oncology, 2017, 28, viii51-viii56.	0.6	200
783	Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Annals of Oncology, 2017, 28, viii36-viii39.	0.6	64
784	Front-line therapy of advanced ovarian cancer: new approaches. Annals of Oncology, 2017, 28, viii46-viii50.	0.6	41
785	Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Annals of Oncology, 2017, 28, 702-710.	0.6	46
786	A Retrospective Study of the Effects of Oncology Pharmacist Participation in Treatment on Therapeutic Outcomes and Medical Costs. Biological and Pharmaceutical Bulletin, 2017, 40, 1956-1962.	0.6	8
788	Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. ESMO Open, 2017, 2, e000225.	2.0	24
789	Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Research, 2017, 6, 84.	0.8	16
790	Whence High-Grade Serous Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 443-448.	1.8	15
791	Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer. Journal of Peritoneum (and Other Serosal Surfaces), 2017, , .	0.1	1
792	Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities. Korean Journal of Radiology, 2017, 18, 28.	1.5	24
793	Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis. Obstetrics and Gynecology Science, 2017, 60, 308.	0.6	4
794	Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. International Journal of Molecular Sciences, 2017, 18, 1967.	1.8	68

#	ARTICLE	IF	CITATIONS
795	Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e45.	1.0	24
796	Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. <i>Cancers</i> , 2017, 9, 83.	1.7	44
797	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 210.	1.8	20
798	Update on immune checkpoint inhibitors in gynecological cancers. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e20.	1.0	49
799	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e54.	1.0	20
801	Vasohibin-1 Is a Poor Prognostic Factor of Ovarian Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 243, 107-114.	0.5	10
802	Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. <i>PLoS Computational Biology</i> , 2017, 13, e1005724.	1.5	38
803	Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 13.	3.6	26
804	Ovarian Cancer: Bevacizumab as Adjuvant Treatmentâ€”Not Yet. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 9-10.	0.1	0
805	Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil. <i>International Heart Journal</i> , 2017, 58, 803-805.	0.5	12
806	Bevacizumab in ovarian cancer: A critical review of phase III studies. <i>Oncotarget</i> , 2017, 8, 12389-12405.	0.8	100
807	Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1521-1525.	1.0	14
808	VSV based virotherapy in ovarian cancer: the past, the present and â€”future?. <i>Journal of Cancer</i> , 2017, 8, 2369-2383.	1.2	10
809	Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 10703-10713.	0.8	52
810	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	0.8	66
811	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e1030-e1039.	2.5	10
812	Reconstructing Time-to-event Data from Published Kaplanâ€”Meier Curves. <i>The Stata Journal</i> , 2017, 17, 786-802.	0.9	157
814	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 18-26.	0.3	1

#	ARTICLE	IF	CITATIONS
815	Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSIA Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 729-737.	1.2	22
816	Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 809-814.	1.1	7
817	Human serum albumin nanoparticles for ocular delivery of bevacizumab. <i>International Journal of Pharmaceutics</i> , 2018, 541, 214-223.	2.6	56
818	Resistance to Inhibitors of Angiogenesis. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 211-236.	0.1	2
819	Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2018, 23, 930-935.	1.0	13
820	High expression of PDXN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 161-165.	0.6	36
821	The role of neoadjuvant chemotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 555-566.	1.1	34
823	The NCI-MATCH trial and precision medicine in gynecologic cancers. <i>Gynecologic Oncology</i> , 2018, 148, 585-590.	0.6	38
824	Management of the toxicities of common targeted therapeutics for gynecologic cancers. <i>Gynecologic Oncology</i> , 2018, 148, 591-600.	0.6	23
825	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors) <i>Tj ETQq1 1 0284314 rgBT /Over</i>	0.6	23
826	Advances in ovarian cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 17-38.	1.1	393
827	PDGFB as a vascular normalization agent in an ovarian cancer model treated with a gamma-secretase inhibitor. <i>Journal of Cellular Physiology</i> , 2018, 233, 5949-5961.	2.0	6
828	Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what mattersâ€”patient-centered end points in trials of maintenance therapy. <i>Annals of Oncology</i> , 2018, 29, 737-743.	0.6	25
829	Frontline therapy of ovarian cancer: trials and tribulations. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 1-6.	0.9	7
830	A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial. <i>Contemporary Clinical Trials</i> , 2018, 65, 151-156.	0.8	0
831	First-line treatment of ovarian cancer: questions and controversies to address. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876823.	1.4	32
832	Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 0, , .	1.5	4
833	Anti-angiogenesis for cancer: Current status and prospects. <i>Thrombosis Research</i> , 2018, 164, S3-S6.	0.8	18

#	ARTICLE	IF	CITATIONS
836	Anti-Angiogenics: Current Situation and Future Perspectives. <i>Oncology Research and Treatment</i> , 2018, 41, 166-171.	0.8	164
838	The Current Landscape of PARP Inhibitors in Ovarian Cancer. <i>Current Obstetrics and Gynecology Reports</i> , 2018, 7, 20-27.	0.3	2
839	Emerging growth factor receptor antagonists for ovarian cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 1-16.	1.0	2
840	Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 2-10.	1.2	37
841	Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). <i>Oncogene</i> , 2018, 37, 722-731.	2.6	34
842	The roles of pathology in targeted therapy of women with gynecologic cancers. <i>Gynecologic Oncology</i> , 2018, 148, 213-221.	0.6	24
843	Revisiting Bevacizumab+â€‰Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Nonâ€‰Small Cell Lung Carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 42-50.	1.3	17
844	Aptamers as potential therapeutic agents for ovarian cancer. <i>Biochimie</i> , 2018, 145, 34-44.	1.3	17
845	Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 196.	3.4	60
846	Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e99-e107.	1.0	2
847	Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 96-106.	1.9	47
848	Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 148, 79-85.	0.6	29
849	Longâ€‰term survival with bevacizumab in heavily pretreated and platinumâ€‰resistant mucinous ovarian cancer: <sc>A</sc> case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 347-351.	0.6	5
850	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. <i>Oncologist</i> , 2018, 23, 203-213.	1.9	28
851	Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. <i>Annals of Surgical Oncology</i> , 2018, 25, 247-254.	0.7	10
852	Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?. <i>Translational Lung Cancer Research</i> , 2018, 7, S179-S182.	1.3	0
853	Antiangiogenesis therapy in ovarian cancer patients. <i>Medicine (United States)</i> , 2018, 97, e11920.	0.4	9
854	Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1592-1599.	1.2	9

#	ARTICLE	IF	CITATIONS
855	Chemotherapy for Primary and Recurrent Epithelial Ovarian Cancer. , 2018, , .		1
856	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .		1
857	Increased expression of Na ⁺ /H ⁺ exchanger isoform 1 predicts tumor aggressiveness and unfavorable prognosis in epithelial ovarian cancer. <i>Oncology Letters</i> , 2018, 16, 6713-6720.	0.8	11
858	ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 886-887.	0.7	0
859	Current First-line Therapy for Ovarian Cancer: A Comprehensive Review. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 650-657.	0.2	9
860	Targeting Angiogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1041-1055.	0.9	11
861	Diagnosis and Treatment of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 943-964.	0.9	185
862	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , 2018, 9, 4672.	5.8	47
863	Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions. <i>Clinical Cancer Drugs</i> , 2018, 5, 3-12.	0.3	0
864	Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2018, 57, 819-824.	0.5	5
865	The safety of bevacizumab for the treatment of ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1107-1113.	1.0	5
866	Secondary cytoreduction in ovarian cancer: who really benefits?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 873-879.	0.8	7
867	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.	1.0	205
868	Targeted therapy for gynecologic cancers: Toward the era of precision medicine. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 131-136.	1.0	17
869	CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. <i>Epigenomics</i> , 2018, 10, 1397-1413.	1.0	14
870	Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e96.	1.0	18
871	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	13.9	1,854
872	Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study. <i>Journal of Surgical Oncology</i> , 2018, 118, 687-693.	0.8	8

#	ARTICLE	IF	CITATIONS
874	Patient-reported outcomes in ovarian cancer: are they key factors for decision making?. Expert Review of Anticancer Therapy, 2018, 18, 3-7.	1.1	11
875	Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2018, 151, 257-263.	0.6	20
876	Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. OncoTargets and Therapy, 2018, Volume 11, 5059-5074.	1.0	23
877	Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases. OncoTargets and Therapy, 2018, Volume 11, 1989-1995.	1.0	5
878	Novel Systemic Treatments in High Grade Ovarian Cancer. , 0, , .		0
879	Carboplatin Dosing Accuracy by Estimation of Glomerular Filtration versus Creatinuria in Cancer Patients. Chemotherapy, 2018, 63, 137-142.	0.8	8
880	Molecular Targeted Therapy for Epithelial Ovarian Cancer. , 2018, , 153-166.		0
881	Clinical Management of Epithelial Ovarian Cancer. , 2018, , 135-151.		0
882	Assessment of the risk of antiangiogenic agents before and after surgery. Cancer Treatment Reviews, 2018, 68, 38-46.	3.4	10
883	Financial toxicity “ An overlooked side effect. Gynecologic Oncology, 2018, 150, 3-6.	0.6	17
884	Gynecologic Cancer. , 2018, , 121-178.		0
886	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clinical Oncology, 2018, 30, 515-524.	0.6	16
887	Metastatic gynecologic malignancies: advances in treatment and management. Clinical and Experimental Metastasis, 2018, 35, 521-533.	1.7	11
888	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). Targeted Oncology, 2018, 13, 469-479.	1.7	38
889	Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. Translational Oncology, 2018, 11, 1053-1064.	1.7	8
890	The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 521-528.	1.0	24
891	Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments. Molecules, 2018, 23, 444.	1.7	11
892	The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. Cancers, 2018, 10, 251.	1.7	111

#	ARTICLE	IF	CITATIONS
893	Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. <i>BMC Cancer</i> , 2018, 18, 601.	1.1	80
894	Dynamic ¹⁸ F-FLT PET imaging of spatiotemporal changes in tumor cell proliferation and vasculature reveals the mechanistic actions of anti-angiogenic therapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 155008.	1.6	6
895	Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 150, 466-470.	0.6	10
896	Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. <i>European Journal of Pharmacology</i> , 2018, 837, 64-71.	1.7	3
897	Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1519-1531.	2.0	21
898	Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. <i>Lancet Oncology</i> , The, 2018, 19, 1239-1246.	5.1	130
899	<i>Gynecologic Cancers.</i> , 2018,, 169-198.		2
900	Paclitaxel and Pazopanib in Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 1298.	3.4	4
901	Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports. <i>Molecular and Clinical Oncology</i> , 2018, 9, 173-177.	0.4	3
902	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. <i>Journal of Controlled Release</i> , 2018, 281, 1-10.	4.8	29
903	Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018, 143, 2187-2199.	2.3	8
906	Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1501-1509.	2.0	27
907	Neovascularization: an attractive but tricky target in thyroid cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 799-810.	1.5	6
908	Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 947-958.	1.1	5
909	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018, 10, 266.	1.7	30
910	LY2157299 Monohydrate, a TGF- β 1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer. <i>Cancers</i> , 2018, 10, 260.	1.7	42
911	The Clearance of Serum Human Epididymis Protein 4 Following Primary Cytoreductive Surgery for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1066-1072.	1.2	2
912	Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?. <i>Cancer Treatment Reviews</i> , 2018, 69, 53-65.	3.4	30

#	ARTICLE	IF	CITATIONS
913	HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. <i>Annals of Oncology</i> , 2018, 29, 1610-1613.	0.6	40
914	Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma. <i>Cancer Letters</i> , 2018, 432, 144-155.	3.2	39
915	Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. <i>British Journal of Cancer</i> , 2018, 119, 12-18.	2.9	9
916	Pro- and antiangiogenic therapies: current status and clinical implications. <i>FASEB Journal</i> , 2019, 33, 34-48.	0.2	56
917	Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022) Tj ETQq0 10 rgBT / Overlock 1	0.0	0
918	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. <i>Health Information and Libraries Journal</i> , 2019, 36, 318-340.	1.3	3
920	Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2416-2419.	0.8	17
921	Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2424-2436.	0.8	29
922	Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2386-2397.	0.8	16
923	Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study. <i>Journal of Surgical Oncology</i> , 2019, 120, 786-793.	0.8	4
924	Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2251-2259.	1.2	2
925	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 505-515.	0.6	11
926	The Evolving Arena of Ovarian Cancer Maintenance Therapy. <i>Oncology</i> , 2019, 97, 202-205.	0.9	2
927	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. <i>Lancet Oncology</i> , The, 2019, 20, e417-e433.	5.1	89
928	Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1629865.	5.5	90
929	Pharmaceutical Management of Ovarian Cancer: Current Status. <i>Drugs</i> , 2019, 79, 1231-1239.	4.9	49
930	Extracapsular Lymph Node Involvement in Ovarian Carcinoma. <i>Cancers</i> , 2019, 11, 924.	1.7	4
931	Cathepsin L-induced galectin-1 may act as a proangiogenic factor in the metastasis of high-grade serous carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 216.	1.8	19

#	ARTICLE	IF	CITATIONS
932	Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 3368-3380.	1.3	14
933	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1929-1939.	13.9	217
934	Prevention of Anastomotic Leakage in Ovarian Cancer Debulking Surgery and Its Impact on Overall Survival. <i>Anticancer Research</i> , 2019, 39, 5209-5218.	0.5	20
935	The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 2435-2439.	0.6	4
936	<p>Application Of Adoptive Immunotherapy In Ovarian Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7975-7991.	1.0	4
938	Bevacizumab prescribing practices for epithelial ovarian cancer in Australia. <i>Internal Medicine Journal</i> , 2019, 49, 1334-1335.	0.5	0
939	Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. <i>Radiation Oncology</i> , 2019, 14, 179.	1.2	11
940	Hopes and failures in front-line ovarian cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 14-19.	2.0	51
941	Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 771-785.	1.9	9
942	Endothelial life discontinues without Erk. <i>Journal of Experimental Medicine</i> , 2019, 216, 1730-1732.	4.2	1
943	Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. <i>Frontiers in Pharmacology</i> , 2019, 10, 426.	1.6	21
944	Reply to R.J. Buckanovich et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2708-2709.	0.8	0
945	Olaparib in the treatment of ovarian cancer. <i>Future Oncology</i> , 2019, 15, 3435-3449.	1.1	13
946	CD47 promotes cell growth and motility in epithelial ovarian cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 119, 109105.	2.5	27
947	Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity. <i>Angiogenesis</i> , 2019, 22, 535-546.	3.7	3
948	Cancer Biomarkers in Body Fluids. , 2019, , .		5
949	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOMA2/ENGOT-ov24): a randomised, phase 2, superiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1409-1419.	5.1	179
950	Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. <i>PLoS ONE</i> , 2019, 14, e0222828.	1.1	0

#	ARTICLE	IF	CITATIONS
951	Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 186-191.	0.6	54
952	Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities. <i>Cancers</i> , 2019, 11, 1389.	1.7	45
953	Rapidly Changing Landscape of Fallopian Tube Carcinoma. <i>Journal of Oncology Practice</i> , 2019, 15, 383-384.	2.5	0
954	EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4693.	1.8	25
955	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	13.9	627
956	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. <i>Journal of Ovarian Research</i> , 2019, 12, 9.	1.3	83
957	Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 67-88.	0.7	12
958	Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 137-154.	0.7	3
960	<p>>Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis</p></p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4119-4128.	0.9	2
961	Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer. <i>Pharmaceutics</i> , 2019, 11, 216.	2.0	17
962	Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 195-202.	1.1	9
963	Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. <i>BMC Cancer</i> , 2019, 19, 584.	1.1	59
964	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2317-2328.	0.8	289
965	<p>>Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil</p></p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4905-4915.	0.9	32
966	In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. <i>Experimental Eye Research</i> , 2019, 185, 107697.	1.2	34
967	Lipid metabolism and Calcium signaling in epithelial ovarian cancer. <i>Cell Calcium</i> , 2019, 81, 38-50.	1.1	36
968	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
969	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	3.2	26

#	ARTICLE	IF	CITATIONS
970	Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. <i>Angiogenesis</i> , 2019, 22, 441-455.	3.7	19
971	Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. <i>British Journal of Cancer</i> , 2019, 121, 109-116.	2.9	38
972	Ovarian cancer and the evolution of subtype classifications using transcriptional profiling. <i>Biology of Reproduction</i> , 2019, 101, 645-658.	1.2	33
973	The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e141-e151.	1.8	14
974	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e152-e166.	1.8	12
975	Low grade serous ovarian carcinoma: identifying variations in practice patterns. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 174-180.	1.2	9
976	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 862-876.	5.1	68
977	A Role for NF- κ B in Organ Specific Cancer and Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 655.	1.7	84
978	<p>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4371-4390.	0.9	77
979	Total and out-of-pocket costs of different primary management strategies in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 136.e1-136.e9.	0.7	25
980	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 280-304.	157.7	821
981	Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1359-1364.	0.8	7
982	An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. <i>Gynecologic Oncology</i> , 2019, 153, 541-548.	0.6	61
983	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	0.6	665
984	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	1.2	167
985	Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1111-1118.	1.0	6
986	Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 552-561.	0.9	10
987	PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. <i>BioDrugs</i> , 2019, 33, 255-273.	2.2	31

#	ARTICLE	IF	CITATIONS
988	Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. <i>Cancers</i> , 2019, 11, 270.	1.7	19
989	Epithelial ovarian cancer. <i>Lancet, The</i> , 2019, 393, 1240-1253.	6.3	1,039
990	Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards. <i>Value in Health</i> , 2019, 22, 431-438.	0.1	11
991	Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years. <i>Gynecologic Oncology</i> , 2019, 153, 479-486.	0.6	6
992	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. <i>Cancers</i> , 2019, 11, 416.	1.7	49
993	Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1175.	1.8	11
994	New and Novel Therapies for Gynecologic Cancers. <i>Seminars in Oncology Nursing</i> , 2019, 35, 217-219.	0.7	10
995	Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 577-587.	0.6	3
997	Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 33-39.	1.1	7
998	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 430-433.	1.2	33
999	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. <i>Clinical Cancer Research</i> , 2019, 25, 5342-5350.	3.2	33
1000	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2019, 153, 555-561.	0.6	19
1001	Gynecological Cancers—the Changing Paradigm. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 156-161.	0.3	0
1002	Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 347-353.	0.6	2
1003	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). <i>Oncology Letters</i> , 2019, 17, 2583-2591.	0.8	16
1004	Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis. <i>Clinical Drug Investigation</i> , 2019, 39, 395-400.	1.1	6
1005	<p>First-line treatment of women with advanced ovarian cancer: focus on bevacizumab</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1095-1103.	1.0	53
1006	Major clinical research advances in gynecologic cancer in 2018. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e18.	1.0	29

#	ARTICLE	IF	CITATIONS
1007	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. <i>New England Journal of Medicine</i> , 2019, 380, 822-832.	13.9	373
1010	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
1011	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. <i>Gynecologic Oncology</i> , 2019, 153, 436-444.	0.6	17
1012	Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. <i>Gynecologic Oncology</i> , 2019, 153, 223-229.	0.6	7
1013	Treatment of recurrent epithelial ovarian cancer. <i>Cancer</i> , 2019, 125, 4609-4615.	2.0	49
1014	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. <i>Asian Journal of Oncology</i> , 2019, 05, 01-18.	0.2	0
1015	Dual specificity phosphatase 6 as a new therapeutic target candidate for epithelial ovarian cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S373-S373.	0.7	1
1016	Dilution of Molecular Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 213-219.	3.2	12
1018	Moving beyond cytotoxic drug dosing in ovarian cancer. <i>Lancet, The</i> , 2019, 394, 2043-2045.	6.3	0
1019	Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4794.	1.2	23
1020	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	13.9	1,176
1021	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
1022	Maintenance Therapy in Metastatic Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 615-623.	0.6	4
1023	Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3913-3918.	2.0	10
1024	High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. <i>Oncology Reports</i> , 2019, 42, 2750-2758.	1.2	7
1025	Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy. <i>Cancer</i> , 2019, 125, 4582-4586.	2.0	23
1026	Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 4-11.	0.9	8
1027	Molecular Assessment of Ovarian Cancer and Translation to Clinical Management. , 2019, , 501-519.		0

#	ARTICLE	IF	CITATIONS
1028	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
1029	Molecular-targeted therapies and precision medicine for endometrial cancer. Japanese Journal of Clinical Oncology, 2019, 49, 108-120.	0.6	38
1030	Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecologic Oncology, 2019, 152, 235-242.	0.6	10
1031	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology, 2019, 152, 53-60.	0.6	40
1032	Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach. International Journal of Peptide Research and Therapeutics, 2019, 25, 1417-1430.	0.9	2
1033	Ovarian carcinosarcoma: Current developments and future perspectives. Critical Reviews in Oncology/Hematology, 2019, 134, 46-55.	2.0	42
1034	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. Pharmacological Research, 2019, 141, 392-396.	3.1	47
1036	A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Investigational New Drugs, 2019, 37, 658-665.	1.2	8
1038	Overview of CD24 as a new molecular marker in ovarian cancer. Journal of Cellular Physiology, 2019, 234, 2134-2142.	2.0	84
1039	Predictive Biomarkers and Targeted Therapies in Gynecological Cancers. , 2019, , 445-456.		0
1040	Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncology, 2019, 15, 543-561.	1.1	10
1041	When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer. Journal of Minimally Invasive Gynecology, 2019, 26, 902-909.	0.3	26
1042	Novel Therapeutic Approaches and Targets for Ovarian Cancer. , 2019, , 547-574.		2
1044	Genetic testing in ovarian cancer â€œ clinical impact and current practices. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	4
1045	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. Abdominal Radiology, 2020, 45, 828-841.	1.0	2
1046	Final results from GCIG/ENGOT/AGOâ€™OVAR 12, a randomised placeboâ€™controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer, 2020, 146, 439-448.	2.3	40
1047	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
1048	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. Annals of Palliative Medicine, 2020, 9, 4430-4445.	0.5	0

#	ARTICLE	IF	CITATIONS
1049	A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 287-295.	1.2	12
1050	Tumor angiogenesis: causes, consequences, challenges and opportunities. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1745-1770.	2.4	927
1051	Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway. <i>International Journal of Cancer</i> , 2020, 146, 2268-2280.	2.3	41
1052	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	3.2	29
1053	Targeted therapies in gynaecological cancers. <i>Histopathology</i> , 2020, 76, 157-170.	1.6	30
1054	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2020, 156, 13-22.	0.6	9
1055	Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 92-108.	0.6	6
1056	Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. <i>International Journal of Cancer</i> , 2020, 147, 1086-1097.	2.3	27
1057	Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. <i>Anti-Cancer Drugs</i> , 2020, 31, 101-109.	0.7	4
1058	Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2020, 156, 32-37.	0.6	17
1059	Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 80-85.	0.6	0
1060	The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 49-55.	2.2	9
1061	The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. <i>Gynecologic Oncology</i> , 2020, 159, 850-859.	0.6	4
1062	Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial. <i>BMC Medicine</i> , 2020, 18, 267.	2.3	7
1063	Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. <i>Gynecologic Oncology</i> , 2020, 159, 491-497.	0.6	16
1064	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 134.	6.9	36
1065	Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1083-1099.	2.5	8
1066	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	1.0	15

#	ARTICLE	IF	CITATIONS
1067	Effect of vascular normalization on drug delivery to different stages of tumor progression: In-silico analysis. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 60, 101989.	1.4	25
1068	Are antiangiogenics a good "partner" for immunotherapy in ovarian cancer?. <i>Angiogenesis</i> , 2020, 23, 543-557.	3.7	10
1069	Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 44-44.	0.4	3
1070	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2559-2574.	1.2	4
1071	Measuring Quality of Life in Ovarian Cancer Clinical Trials"Can We Improve Objectivity and Cross Trial Comparisons?. <i>Cancers</i> , 2020, 12, 3296.	1.7	13
1072	A retrospective analysis of emergency surgery for cases of acute abdomen during cancer chemotherapy. Case series. <i>Annals of Medicine and Surgery</i> , 2020, 57, 143-147.	0.5	5
1073	Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 758.	1.8	97
1074	The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2239.	1.0	24
1075	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 137.	7.1	79
1076	Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1095.	1.3	8
1077	Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 703.	1.1	22
1078	Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 142-149.	0.6	30
1079	Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. <i>Gynecologic Oncology</i> , 2020, 159, 88-94.	0.6	16
1080	Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study. <i>Gynecologic Oncology</i> , 2020, 159, 95-100.	0.6	10
1081	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	0.6	6
1082	Effects of naringin on reversing cisplatin resistance and the Wnt/ β -catenin pathway in human ovarian cancer SKOV3/CDDP cells. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988786.	0.4	12
1083	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. <i>Cancer Treatment Reviews</i> , 2020, 90, 102107.	3.4	21
1085	Anti-angiogenic therapy for ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 77-86.	2.2	8

#	ARTICLE	IF	CITATIONS
1086	Novel monoclonal antibody against integrin $\alpha 3$ shows therapeutic potential for ovarian cancer. <i>Cancer Science</i> , 2020, 111, 3478-3492.	1.7	5
1087	First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab - our experience. <i>Libri Oncologici</i> , 2020, 47, 64-70.	0.1	1
1088	Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2155-2162.	1.9	4
1089	Frontline Management of Epithelial Ovarian Cancer – Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. <i>Journal of Clinical Medicine</i> , 2020, 9, 2830.	1.0	4
1090	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1608-1618.	1.2	4
1091	EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1470-1474.	0.6	5
1092	Front-Line Maintenance Therapy in Advanced Ovarian Cancer – Current Advances and Perspectives. <i>Cancers</i> , 2020, 12, 2414.	1.7	10
1093	Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1087-1102.	0.8	31
1094	The clinical impact of intra- and extracellular miRNAs in ovarian cancer. <i>Cancer Science</i> , 2020, 111, 3435-3444.	1.7	41
1095	Breast cancer (BRCA) gene testing in ovarian cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 63-63.	0.4	3
1097	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1748-1756.	1.2	24
1098	First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. <i>ESMO Open</i> , 2020, 5, e001110.	2.0	42
1099	Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9492.	1.8	28
1100	Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. <i>Tumor Biology</i> , 2020, 42, 101042832097140.	0.8	6
1101	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1603-1607.	1.2	4
1102	Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors. <i>Anticancer Research</i> , 2020, 40, 6923-6931.	0.5	12
1103	Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 5583.	5.8	99
1104	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 583-601.	1.0	4

#	ARTICLE	IF	CITATIONS
1105	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e116-e131.	1.8	30
1106	Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer: An Age-Stratified Study of 1123 Women from the FRANCOGYN Group. Journal of Clinical Medicine, 2020, 9, 1451.	1.0	12
1107	Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer. In Vivo, 2020, 34, 1451-1457.	0.6	1
1108	Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. Advances in Therapy, 2020, 37, 2829-2840.	1.3	2
1109	The untapped potential of ascites in ovarian cancer research and treatment. British Journal of Cancer, 2020, 123, 9-16.	2.9	108
1110	Immunology and ovarian cancers. Journal of the Chinese Medical Association, 2020, 83, 425-432.	0.6	28
1111	Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin β -II-Overexpressing Ovarian Carcinoma. Anticancer Research, 2020, 40, 2497-2507.	0.5	4
1112	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 1206.	1.7	6
1113	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecologic Oncology, 2020, 158, 16-24.	0.6	40
1114	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews, 2020, 87, 102040.	3.4	35
1115	Rare ovarian tumors: an update on diagnosis and treatment. International Journal of Gynecological Cancer, 2020, 30, 879-887.	1.2	14
1116	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Frontiers in Oncology, 2020, 10, 570.	1.3	127
1117	Current and future strategies for treatment of ovarian clear cell carcinoma. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1678-1689.	0.6	9
1118	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. Current Oncology Reports, 2020, 22, 64.	1.8	30
1119	Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence. International Journal of Clinical Oncology, 2020, 25, 1726-1735.	1.0	8
1120	Perioperative blood transfusion and ovarian cancer survival rates: A meta-analysis based on univariate, multivariate and propensity score matched data. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 137-143.	0.5	5
1121	The Potential of Tumor Debulking to Support Molecular Targeted Therapies. Frontiers in Oncology, 2020, 10, 801.	1.3	6
1122	Bevacizumab-related gastrointestinal perforation in patients with three or more prior chemotherapy regimens: A real-world experience. Taiwanese Journal of Obstetrics and Gynecology, 2020, 59, 377-380.	0.5	4

#	ARTICLE	IF	CITATIONS
1123	The forefront of ovarian cancer therapy: update on PARP inhibitors. <i>Annals of Oncology</i> , 2020, 31, 1148-1159.	0.6	191
1124	Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction. <i>Gynecologic Oncology</i> , 2020, 158, 603-607.	0.6	11
1125	State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1579-1590.	0.9	10
1126	The emerging role of precision medicine in the treatment of ovarian cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 283-297.	0.4	3
1127	The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs. <i>Frontiers in Oncology</i> , 2020, 10, 806.	1.3	2
1128	The recent progress and therapy in endometriosis-associated ovarian cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 227-232.	0.6	23
1129	Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1335-1341.	1.2	4
1130	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2020, 157, 599-605.	0.6	5
1131	Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. <i>Future Oncology</i> , 2020, 16, 225-246.	1.1	63
1132	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020, 10, 146.	1.3	56
1133	Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis. <i>Future Oncology</i> , 2020, 16, 585-596.	1.1	13
1134	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa026.	1.4	21
1135	Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. <i>Cancers</i> , 2020, 12, 1676.	1.7	32
1136	<p>Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6109-6129.	1.0	54
1137	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020, 15, e0235766.	1.1	2
1138	Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer. <i>Chemotherapy</i> , 2020, 65, 54-57.	0.8	2
1139	The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 151.	0.8	14
1140	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 379-385.	0.6	89

#	ARTICLE	IF	CITATIONS
1141	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1239-1251.	3.3	12
1142	Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 379-386.	0.6	23
1143	Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. <i>Gynecologic Oncology</i> , 2020, 157, 386-391.	0.6	25
1144	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	0.6	14
1145	Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. <i>Current Cancer Drug Targets</i> , 2020, 20, 3-18.	0.8	43
1146	The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice. <i>Acta OncolÃ³gica</i> , 2020, 59, 453-457.	0.8	1
1147	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567.	0.6	21
1148	Angiocrine endothelium: from physiology to cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 52.	1.8	53
1149	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 49.	1.3	7
1150	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. <i>Cells</i> , 2020, 9, 903.	1.8	8
1151	<scp>ABCC4</scp>/<scp>MRP4</scp> contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 2225-2238.	2.3	11
1152	Targeting tumor microenvironment in ovarian cancer: Premise and promise. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188361.	3.3	105
1153	Ovarian cancer treatment is evolving: more choices, more chances. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 726-727.	1.2	0
1154	Comparing Paclitaxelâ€“Carboplatin with Paclitaxelâ€“Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIc Serous-Type Tubo-Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2213.	1.2	33
1155	Bevacizumab (AvastinÂ®) in cancer treatment: A review of 15Âyears of clinical experience and future outlook. <i>Cancer Treatment Reviews</i> , 2020, 86, 102017.	3.4	573
1156	Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 213-220.	1.2	22
1157	Carboplatin dosing in the era of IDMS-creatinine; the Cockcroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. <i>Gynecologic Oncology</i> , 2020, 157, 793-798.	0.6	8
1158	Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1409-1420.	1.1	28

#	ARTICLE	IF	CITATIONS
1159	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. <i>Annals of Surgical Oncology</i> , 2020, 27, 1780-1787.	0.7	13
1160	Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study. <i>Anticancer Research</i> , 2020, 40, 1543-1550.	0.5	1
1161	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. <i>Cancer</i> , 2020, 126, 2553-2560.	2.0	11
1162	Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?. <i>Clinical and Translational Oncology</i> , 2021, 23, 536-542.	1.2	5
1163	Impact of nonspecific death on overall survival in early-stage epithelial ovarian cancer patients. <i>Current Problems in Cancer</i> , 2021, 45, 100621.	1.0	0
1164	PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 485-493.	1.1	23
1165	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 598-605.	1.0	6
1166	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 277-288.	5.1	34
1167	Asian perspective on debulking surgery for advanced ovarian cancer: An E-survey. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1111-1116.	0.5	3
1168	Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population. <i>Laryngoscope</i> , 2021, 131, E921-E928.	1.1	11
1169	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	0.6	8
1170	A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 54-59.	0.6	2
1172	The vascular landscape of human cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	26
1173	SEOM clinical guideline in ovarian cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 961-968.	1.2	22
1174	Application of Second-Generation Sequencing in the Diagnosis and Treatment of Gynecological Tumors. <i>Advances in Clinical Medicine</i> , 2021, 11, 2689-2697.	0.0	0
1175	A Single Arm Prospective Pilot Study Examining the Efficacy and Safety of Bevacizumab Single Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Advanced or Recurrent Cervical Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 145-153.	0.5	4
1176	Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110496.	1.4	12
1177	Metastatic ovarian cancer to the gallbladder indicative of the diagnosis. <i>MOJ Clinical & Medical Case Reports</i> , 2021, 11, 14-16.	0.0	0

#	ARTICLE	IF	CITATIONS
1178	<sc>PARP</sc> inhibitors in ovarian cancer: An overview of the practice-changing trials. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 385-397.	1.5	51
1179	Chemoresistance in female-specific cancers and the associated anti-resistance therapies. , 2021, , 49-69.		0
1180	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	2.3	356
1181	Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 550.	1.7	6
1182	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 267-276.	5.1	79
1183	Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 1.	0.1	2
1184	Publication of oral and video presentations from the Society of Gynecologic Oncology annual meeting over 11 years – What characteristics were important?. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100688.	0.3	2
1185	Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 4219.	1.6	37
1186	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103209.	2.0	11
1187	ASO Author Reflections: Clinical Significance of Mesenteric Lymph Node Involvement in Patients with Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7614-7615.	0.7	0
1188	Ovarian Cancer-Associated Mesothelial Cells: Transdifferentiation to Minions of Cancer and Orchestrate Developing Peritoneal Dissemination. <i>Cancers</i> , 2021, 13, 1352.	1.7	20
1189	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management. <i>Thrombosis Research</i> , 2021, 199, 38-42.	0.8	6
1190	Creation and validation of models to predict response to primary treatment in serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 5957.	1.6	13
1191	Cáncer de ovario. <i>Medicine</i> , 2021, 13, 1518-1526.	0.0	0
1192	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 1076.	1.7	5
1193	Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 510-510.	0.7	13
1194	Ovarian Carcinoma with Peritoneal Metastasis: Rethinking of Management. <i>Archives of Clinical and Experimental Medicine</i> , 2021, 6, 32-36.	0.1	0
1195	Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 622752.	1.3	9

#	ARTICLE	IF	CITATIONS
1196	An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Current Oncology</i> , 2021, 28, 1114-1124.	0.9	4
1197	Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era. <i>International Journal of Hematology</i> , 2021, 114, 189-198.	0.7	5
1198	Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma. <i>Cancers</i> , 2021, 13, 1875.	1.7	16
1199	Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. <i>Gynecologic Oncology</i> , 2021, 161, 244-250.	0.6	6
1200	Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. <i>ESMO Open</i> , 2021, 6, 100043.	2.0	16
1201	PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience. <i>JCO Global Oncology</i> , 2021, 7, 506-511.	0.8	10
1202	Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications. <i>Gynecologic Oncology</i> , 2021, 161, 78-82.	0.6	21
1204	Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 658-669.	1.2	5
1205	Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients. <i>South Asian Journal of Cancer</i> , 2021, 10, 131-134.	0.2	3
1206	Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7606-7613.	0.7	5
1207	Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1055-1063.	0.8	5
1208	Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00918.	1.4	2
1209	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 875-882.	1.2	19
1210	Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 501.	0.8	5
1211	Narrative review of novel chemotherapeutic agents in management of ovarian cancer. <i>Gynecology and Pelvic Medicine</i> , 0, 4, 19-19.	0.1	0
1212	Emergent Bowel Surgery Following Treatment with Bevacizumab. <i>Journal of Gynecologic Surgery</i> , 0, , .	0.0	1
1213	Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort. <i>BMC Cancer</i> , 2021, 21, 525.	1.1	3
1214	The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2021, 161, 601-612.	0.6	16

#	ARTICLE	IF	CITATIONS
1215	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	3.2	54
1217	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 374-381.	0.6	17
1218	Programmed death ligand 1 regulates angiogenesis and metastasis by participating in the c-MYC/JUN/VEGFR2 signaling axis in ovarian cancer. <i>Cancer Communications</i> , 2021, 41, 511-527.	3.7	31
1219	Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , 2021, 161, 382-388.	0.6	7
1220	RECENT PROGRESS IN OVARIAN CANCER THERAPY. <i>Medico Oncology</i> , 2020, 1, 53-60.	0.3	0
1221	Sphingolipids as multifaceted mediators in ovarian cancer. <i>Cellular Signalling</i> , 2021, 81, 109949.	1.7	8
1222	Bevacizumab in advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 720-726.	0.6	11
1223	A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	66
1224	FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3065.	1.7	37
1225	Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline. <i>JCO Global Oncology</i> , 2021, 7, 1032-1066.	0.8	21
1226	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II-IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103324.	2.0	6
1227	Frontline Maintenance Treatment for Ovarian Cancer. <i>Current Oncology Reports</i> , 2021, 23, 97.	1.8	3
1228	Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3177.	1.7	15
1229	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103336.	2.0	3
1230	Malformin-A1 (MA1) Sensitizes Chemo-resistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis. <i>Molecules</i> , 2021, 26, 3624.	1.7	5
1231	Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer. <i>Future Oncology</i> , 2021, 17, 2291-2304.	1.1	2
1232	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	0.8	183
1233	Multimodal Treatment of Primary Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 3253-3260.	0.5	14

#	ARTICLE	IF	CITATIONS
1234	Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 262, 13-20.	0.5	3
1236	The Complement System in Ovarian Cancer: An Underexplored Old Path. <i>Cancers</i> , 2021, 13, 3806.	1.7	5
1237	Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2022, 34, 221-234.	0.7	3
1238	An Ominous Sign: Mucinous Ovarian Carcinoma with Sister Mary Joseph Nodule. <i>Journal of the Nuffield Department of Surgical Sciences</i> , 2021, 2, .	0.0	0
1239	A ten-gene methylation signature as a novel biomarker for improving prediction of prognosis and indicating gene targets in endometrial cancer. <i>Genomics</i> , 2021, 113, 2032-2044.	1.3	10
1240	Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer. <i>Ecancermedicalscience</i> , 2021, 15, 1262.	0.6	2
1241	Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. <i>Cancer Cell</i> , 2021, 39, 928-944.e6.	7.7	158
1242	A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. <i>Gynecologic Oncology</i> , 2021, 162, 292-298.	0.6	9
1243	Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. <i>Gynecologic Oncology</i> , 2021, 163, 57-63.	0.6	6
1244	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	1.2	3
1245	The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 78, 14-14.	1.4	0
1246	Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 683-691.	0.8	7
1247	Gynecologic Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 621-628.	0.2	0
1248	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. <i>Acta Clinica Belgica</i> , 2021, , 1-13.	0.5	4
1249	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2021, 162, 482-495.	0.6	31
1250	The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts. <i>Gynecologic Oncology</i> , 2021, 162, 245-248.	0.6	0
1251	An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions. <i>Oncology and Therapy</i> , 2021, 9, 347-364.	1.0	10
1252	Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence— results of a prospective multi-centre study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2150-2157.	0.5	5

#	ARTICLE	IF	CITATIONS
1253	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4438.	1.7	40
1254	Role of adjuvant and post-surgical treatment in gynaecological cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 2-13.	1.4	9
1255	Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance. <i>Cancers</i> , 2021, 13, 4471.	1.7	10
1256	Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. <i>International Journal of Cancer</i> , 2022, 150, 279-289.	2.3	8
1257	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1589-1594.	1.2	40
1258	Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. <i>Anticancer Research</i> , 2021, 41, 4673-4685.	0.5	8
1259	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. <i>Cancers</i> , 2021, 13, 4553.	1.7	6
1260	Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 711813.	1.6	9
1261	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 64-73.	1.4	9
1262	Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. <i>Cancers</i> , 2021, 13, 4444.	1.7	42
1263	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
1264	Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. <i>Cancers</i> , 2021, 13, 4739.	1.7	2
1265	A note on confidence intervals for the restricted mean survival time based on transformations in small sample size. <i>Pharmaceutical Statistics</i> , 2021, , .	0.7	1
1266	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1275-1289.	5.1	118
1267	Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4603.	1.7	10
1268	Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. <i>European Journal of Cancer</i> , 2021, 157, 415-423.	1.3	18
1269	Evidence-based medicine and clinical epidemiology. , 2022, , 106-115.e2.		0
1270	Molecular oncology in gynecologic cancer. , 2022, , 606-617.e3.		0

#	ARTICLE	IF	CITATIONS
1271	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
1272	Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol. <i>BMJ Open</i> , 2021, 11, e041463.	0.8	13
1273	Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer. <i>BMC Cancer</i> , 2021, 21, 67.	1.1	4
1274	Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRAALGIA study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 533-541.	1.1	3
1275	How to win the ovarian cancer stem cell battle: destroying the roots. , 2020, 3, 1021-1033.		6
1276	Trial Design: Should Randomized Phase III Trials in Gynecological Cancers Be Abandoned?. , 2014, , 263-284.		1
1277	Cathepsin D in the Tumor Microenvironment of Breast and Ovarian Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1259, 1-16.	0.8	17
1278	Adnexe. , 2013, , 529-564.		3
1279	Gynecologic Cancers. , 2014, , 645-656.		1
1280	Concordance Between Tumor and Germline <i>BRCA</i> Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 917-923.	3.0	26
1281	EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. <i>JCI Insight</i> , 2019, 4, .	2.3	88
1282	Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	74
1283	Predicting time to ovarian carcinoma recurrence using protein markers. <i>Journal of Clinical Investigation</i> , 2013, 123, 3740-50.	3.9	46
1284	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	3.9	101
1285	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 589-606.	3.9	105
1286	Reconstructing Time-to-event Data from Published Kaplan-Meier Curves. <i>The Stata Journal</i> , 2017, 17, 786-802.	0.9	4
1287	Renal insufficiency in patients on PARP inhibitors: Case-based review of possible mechanisms and management. <i>Journal of Onco-Nephrology</i> , 2021, 5, 8-12.	0.3	1
1288	PVT1 Promotes Angiogenesis by Regulating miR-29c/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway in Non-Small-Cell Lung Cancer (NSCLC). <i>Medical Science Monitor</i> , 2019, 25, 5418-5425.	0.5	37

#	ARTICLE	IF	CITATIONS
1289	New developments in the anti-neoplastic drug management of ovarian cancer. <i>F1000prime Reports</i> , 2013, 5, 48.	5.9	1
1290	Therapeutic strategies for targeting the ovarian tumor stroma. <i>World Journal of Clinical Cases</i> , 2014, 2, 194.	0.3	16
1291	ALDH1-High Ovarian Cancer Stem-Like Cells Can Be Isolated from Serous and Clear Cell Adenocarcinoma Cells, and ALDH1 High Expression Is Associated with Poor Prognosis. <i>PLoS ONE</i> , 2013, 8, e65158.	1.1	91
1292	Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e81858.	1.1	36
1293	Automated Detection of Off-Label Drug Use. <i>PLoS ONE</i> , 2014, 9, e89324.	1.1	47
1294	An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e89960.	1.1	27
1295	Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e102484.	1.1	70
1296	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e107643.	1.1	17
1297	CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0139237.	1.1	59
1298	The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. <i>PLoS ONE</i> , 2016, 11, e0158208.	1.1	28
1299	Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo. <i>PLoS ONE</i> , 2016, 11, e0159739.	1.1	8
1300	Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. <i>PLoS ONE</i> , 2017, 12, e0175703.	1.1	8
1301	miRNAs as tools for tailoring personalized therapeutic strategies in ovarian carcinoma. <i>RNA & Disease (Houston, Tex)</i> , 0, , .	1.0	1
1302	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	0.8	15
1303	Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. <i>Oncotarget</i> , 2016, 7, 82741-82756.	0.8	10
1304	Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. <i>Oncotarget</i> , 2017, 8, 51492-51506.	0.8	38
1305	Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. <i>Oncotarget</i> , 2017, 8, 74494-74505.	0.8	35
1306	A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. <i>Oncotarget</i> , 2014, 5, 11154-11167.	0.8	14

#	ARTICLE	IF	CITATIONS
1307	Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy. <i>Oncotarget</i> , 2020, 11, 99-114.	0.8	9
1308	Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 23548-23560.	0.8	35
1309	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. <i>Oncotarget</i> , 2015, 6, 30057-30071.	0.8	15
1310	High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. <i>Oncotarget</i> , 2015, 6, 35813-35829.	0.8	51
1311	Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. <i>Oncotarget</i> , 2016, 7, 13221-13227.	0.8	21
1312	Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 8993-9006.	0.8	66
1313	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.	0.8	9
1314	Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. <i>Annals of Translational Medicine</i> , 2020, 8, 1687-1687.	0.7	6
1315	NOTCH signalling in ovarian cancer angiogenesis. <i>Annals of Translational Medicine</i> , 2020, 8, 1705-1705.	0.7	24
1316	Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico. <i>Salud Publica De Mexico</i> , 2016, 58, 302-308.	0.1	6
1317	Biomarkers for Systemic Therapy in Ovarian Cancer. <i>Current Cancer Drug Targets</i> , 2014, 14, 259-273.	0.8	6
1318	Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in "Real-world" Patients. <i>Anticancer Research</i> , 2016, 36, 4947-4950.	0.5	5
1319	New medical approaches in advanced ovarian cancer. <i>Minerva Medica</i> , 2019, 110, 367-384.	0.3	6
1320	A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2020, 61, 284.	0.9	6
1321	The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis. <i>Cancers</i> , 2015, 7, 1994-2011.	1.7	72
1322	Mucinous Cancer of the Ovary: Overview and Current Status. <i>Diagnostics</i> , 2020, 10, 52.	1.3	65
1323	Personalized medicine in gastric cancer: Where are we and where are we going?. <i>World Journal of Gastroenterology</i> , 2016, 22, 1160.	1.4	37
1324	Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e5.	1.0	7

#	ARTICLE	IF	CITATIONS
1325	Tolerability of Bevacizumab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e6.	1.0	10
1326	PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	16
1327	Targeted therapy of ovarian cancer including immune check point inhibitor. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 798-804.	0.7	40
1328	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. <i>Translational Lung Cancer Research</i> , 2015, 4, 36-54.	1.3	499
1330	Current Possible Drug Therapies for Ovarian Cancer. <i>Journal of Cancer Therapy</i> , 2014, 05, 1203-1214.	0.1	2
1331	Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. <i>Modern Chemotherapy</i> , 2013, 02, 19-32.	0.5	6
1332	Surviving Cancer without a Broken Heart. <i>Rambam Maimonides Medical Journal</i> , 2019, 10, e0012.	0.4	5
1333	Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. <i>World Journal of Experimental Medicine</i> , 2014, 4, 58.	0.9	12
1334	New Therapies for Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 619-621.	2.3	19
1335	Salvage Therapy of Gemcitabine Plus Endostar Significantly Improves Progression-free Survival (PFS) with Platinum-resistant Recurrent Epithelial Ovarian Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 1841-1846.	0.5	8
1336	Efficacy and Toxicity of Anti-VEGF Agents in Patients with Castration-Resistant Prostate Cancer: a Meta-analysis of Prospective Clinical Studies. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 8177-8182.	0.5	5
1337	Novel Directions in Adjuvant Chemotherapy for Early Stage Epithelial Ovarian Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 4157-4160.	0.5	3
1338	Chemotherapy of ovarian cancer in elderly patients. <i>Cancer Biology and Medicine</i> , 2015, 12, 292-301.	1.4	10
1339	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
1340	An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. , 2021, , 19-57.		0
1341	Ovarian Cancer: Primary Advanced and Recurrent Disease. <i>UNIPA Springer Series</i> , 2021, , 861-883.	0.1	0
1342	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e95.	1.0	5
1344	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	1.0	145

#	ARTICLE	IF	CITATIONS
1345	Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. <i>Frontiers in Oncology</i> , 2021, 11, 752127.	1.3	9
1346	Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma. <i>Cancer Science</i> , 2021, 112, 4977-4986.	1.7	12
1347	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. <i>Biomedicines</i> , 2021, 9, 1384.	1.4	4
1348	Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer. <i>Journal of the Chinese Medical Association</i> , 2021, Publish Ahead of Print, .	0.6	12
1349	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. <i>Cancers</i> , 2021, 13, 5152.	1.7	7
1350	Ovarian cancer—ASCO annual meeting update 2021. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 342.	0.3	1
1351	Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). <i>Gynecologic Oncology</i> , 2022, 164, 18-26.	0.6	4
1352	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 4829.	1.0	3
1353	Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients. <i>International Journal of Clinical Oncology</i> , 2022, 27, 441-447.	1.0	2
1355	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>Yearbook of Oncology</i> , 2012, 2012, 104-105.	0.1	0
1357	Dose-Dense Chemotherapy and Neoadjuvant Chemotherapy for Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 349-354.	1.8	0
1358	<i>Gynecologic Cancer</i> , 2013, , 163-246.		0
1359	Management of Recurrent Ovarian Cancer in Older Women., 2013, , 229-242.		0
1360	Ovarian Cancer Relapse: Experimental Therapies., 2013, , 199-228.		0
1361	Molecular Imaging of Ovarian Carcinoma., 2013, , 479-496.		0
1362	Bevacizumab in the Management of Epithelial Ovarian Cancer. <i>Oncology & Hematology Review</i> , 2013, 09, 129.	0.2	0
1363	Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer. <i>World Journal of Obstetrics and Gynecology</i> , 2013, 2, 143.	0.5	1
1364	Molecular Oncology in Gynecologic Cancer., 2013, , 623-633.		1

#	ARTICLE	IF	CITATIONS
1366	Angiogenesis in Gynecologic Cancers. , 2013, , 357-385.		0
1368	Targeted Molecular Therapy for Patients with Ovarian Cancer. , 2014, , 199-222.		0
1369	Treatment of Advanced Stage Ovarian Cancer. , 2014, , 173-184.		0
1370	Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?. , 2014, , 91-100.		0
1371	Strategies for the Management of Ovarian Cancer. , 2014, , 113-116.		0
1373	MET Inhibitors. , 2013, , 209-234.		1
1374	Ovarium- en tubacarcinoom. , 2014, , 159-167.		0
1375	Treatment with bevacizumab in ovarian cancer – clinical trials review. Current Gynecologic Oncology, 2013, 11, 286-294.	0.1	0
1376	The Acute Physiological Effects of the Vaso-Active Drug, L-NNA, a Nitric Oxide Synthase Inhibitor, on Renal and Tumour Perfusion in Human Subjects. Journal of Cancer Therapy, 2014, 05, 44-52.	0.1	0
1377	The Prognostic and Predictive Value of VEGF Across Various Tumor Types. , 2014, , 479-492.		1
1378	The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy. , 2014, , 99-109.		0
1379	Angio-Inhibitors in Ovarian Cancer. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
1380	Metronomic Chemotherapy in Gynecological Cancers. , 2014, , 203-216.		0
1381	Cancers Arising in the Ovary. , 2014, , 1592-1613.e6.		1
1382	Advances in the Medical Management of Ovarian Cancer. , 2014, , 77-107.		0
1383	Cancer of Ovary (Epithelial Ovarian Cancer). , 2014, , 349-436.		0
1384	Epithelial Ovarian Cancer, Low Malignant Potential, and Sex Cord Stromal Tumors of the Ovary. , 2015, , 3-53.		1
1387	Treatment of Early Ovarian Cancer. , 2015, , 419-427.		0

#	ARTICLE	IF	CITATIONS
1390	Clinical Trials of PARP Inhibitors with Chemotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 511-531.	0.2	0
1392	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
1394	Ovarian cancer and malignant bowel obstruction. , 2015, , 63-76.		0
1396	Angiogenesis in gynecologic malignancies. <i>Current Gynecologic Oncology</i> , 2015, 13, 256-262.	0.1	1
1397	Angiogenesis Inhibition in Breast Cancer. , 2016, , 589-616.		0
1398	Commentary on Bevacizumab in Ovarian Cancer: Focus on Clinical Data and Future Perspectives. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 0, s5, .	0.1	0
1399	Management of Antiangiogenic Agents. , 2016, , 69-77.		1
1400	Epithelial Ovarian Cancers: On-Target is Better than Near-Target. <i>Chemotherapy</i> , 2016, 05, .	0.0	0
1401	Ovarialtumoren. , 2016, , 281-315.		0
1402	Antiangiogenic Therapy in Epithelial Ovarian Cancer. , 0, , .		0
1403	A case report of long term bevacizumab treatment in multiresistant ovarian cancer. <i>International Journal of Cancer Therapy and Oncology</i> , 2016, 4, 4214.	0.2	0
1404	Treatment at Relapse (Surgery and Systemic Treatments). , 2017, , 133-142.		0
1405	Clinical Research in France, Europe, and in the World Dedicated to Ovarian Cancers. , 2017, , 3-12.		0
1406	First-Line Systemic Therapy (Chemo/Antiangiogenics). , 2017, , 95-112.		0
1407	Endometrioid Carcinoma of the Ovary. , 2017, , 211-220.		0
1408	Surgical Emergencies in Gynecologic Oncology. , 2017, , 219-231.		0
1409	Erkrankungen der Adnexe. , 2017, , 453-504.		1
1410	Cardiotoxicity in Long-Term Survivors. , 2017, , 291-308.		0

#	ARTICLE	IF	CITATIONS
1411	The Value of Anti-angiogenics in Ovarian Cancer Therapy. , 2017, , 1-15.		0
1412	Signal Transduction and Targeted Therapy for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 23-67.	0.0	0
1413	Ovarialkarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-11.		0
1414	Management of Ovarian Cancer in the Elderly Population. Comprehensive Gynecology and Obstetrics, 2017, , 281-303.	0.0	0
1415	OBSOLETE: Ovarian cancer. , 2017, , .		0
1416	Diversity in Pathology and Genomics in Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 117-126.	0.0	0
1417	Primary Chemotherapy and Targeted Molecular Therapy of Epithelial Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 207-224.	0.0	0
1418	Strategies for the Management of Epithelial Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 155-164.	0.0	0
1420	Advances and Perspectives in the Treatment of High-Grade Serous Ovarian Cancer. , 2017, , 1-5.		0
1422	Case 1 " Stage IV low-grade serous ovarian carcinoma management in an elderly patient. Cancer Breaking News, 2017, 5, 39-45.	0.0	0
1423	Ovarian carcinoma glyco-antigen targeted by human IgM antibody. PLoS ONE, 2017, 12, e0187222.	1.1	3
1424	Interim Analyses: Design and Analysis Considerations for Survival Trials When Hazards May Be Nonproportional. ICSA Book Series in Statistics, 2018, , 347-376.	0.0	0
1425	Gynecological Symptoms. , 2018, , 505-526.		0
1426	Ovarialkarzinom bei der alten und geriatrischen Patientin. , 2018, , 417-427.		0
1427	Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer. Anticancer Research, 2018, 38, 1517-1523.	0.5	5
1428	Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
1429	Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery. Anticancer Research, 2018, 38, 2247-2252.	0.5	1
1431	Bevacizumab in epithelial ovarian cancer treatment, efficiency and risks. Onkologie (Czech Republic), 2018, 12, 198-202.	0.0	0

#	ARTICLE	IF	CITATIONS
1432	Maligne epitheliale Tumoren des Ovars. , 2019, , 101-129.		0
1433	Modern aspects of antiangiogenic therapy in ovarian cancer. Meditsinskiy Sovet, 2018, , 17-21.	0.1	0
1434	Addition of bevacizumab to adjuvant chemotherapy paclitaxel and carboplatin for cancer ovary. is there a difference?. Journal of Cancer Prevention & Current Research, 2018, 9, .	0.1	0
1435	Ovarian cancer practice survey from the South Asian Association for Regional Cooperation (SAARC) Nations. Cancer Research Statistics and Treatment, 2019, 2, 158.	0.1	2
1436	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
1437	Ovarian Cancer Biomarkers in Proximal Fluids. , 2019, , 191-209.		0
1438	Angiogenesis Inhibition in Breast Cancer. , 2019, , 507-528.		0
1439	The Value of Anti-angiogenics in Ovarian Cancer Therapy. , 2019, , 529-543.		0
1440	Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. World Journal of Clinical Oncology, 2019, 10, 201-212.	0.9	0
1441	Spectrum of Pharmacological Activity of Monoclonal Antibodies. Ukraïns'kij Å¾urnal Medicini Bã¼ologã¼ Ta Sportu, 2019, 4, 17-32.	0.0	0
1442	Informatics Methods for Molecular Profiling. Computers in Health Care, 2020, , 107-132.	0.2	0
1443	Primary ovarian cancer: possibilities for improving treatment outcomes. Meditsinskiy Sovet, 2019, , 150-156.	0.1	1
1444	Regional Therapy for the Treatment of Ovarian Cancer: HIPEC and Intraperitoneal Chemotherapy. , 2020, , 125-140.		0
1445	Risk of Hypertension Associated with Antivascular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	2
1447	Is it possible to improve primary therapy of advanced ovarian cancer?. Meditsinskiy Sovet, 2020, , 128-135.	0.1	0
1448	Bevacizumab in maintenance therapy for ovarian cancer patients. South Russian Journal of Cancer, 2020, 1, 67-74.	0.1	2
1449	Efficacy and safety of standard of care with/without bevacizumab for platinumã¼resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. Cancer Science, 2022, 113, 240-250.	1.7	17
1450	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. British Journal of Cancer, 2021, , .	2.9	3

#	ARTICLE	IF	CITATIONS
1451	Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immuno-engineering. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 378-386.	2.0	1
1452	Adverse events of targeted therapies approved for women's cancers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 552-559.	1.1	0
1454	Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2020, 20, 853-867.	0.8	1
1455	A therapeutic approach to low-grade serous ovarian carcinoma. <i>Libri Oncologici</i> , 2020, 48, 109-115.	0.1	0
1456	Immunology and Immunotherapy of Ovarian Cancer. , 2020, , 487-540.		0
1457	Upfront Maintenance Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors in Ovarian Cancer: A Ray of Hope or Just a Mirage!. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 173-181.	0.1	0
1458	Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. <i>Medical Decision Making</i> , 2021, , 0272989X2110262.	1.2	0
1459	CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7647-7657.	0.8	16
1460	Maligne epitheliale Tumoren des Ovars. , 2014, , 109-134.		1
1461	High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer. <i>PLoS ONE</i> , 2020, 15, e0241484.	1.1	10
1462	A novel method for detecting extra-home range movements (EHRMs) by animals and recommendations for future EHRM studies. <i>PLoS ONE</i> , 2020, 15, e0242328.	1.1	6
1463	New strategy for overcoming resistance to chemotherapy of ovarian cancer. <i>Yonago Acta Medica</i> , 2013, 56, 43-50.	0.3	46
1464	Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 129-39.	0.0	74
1466	Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 274-9.	0.6	6
1467	Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3803-10.	0.5	40
1468	Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. <i>American Journal of Cancer Research</i> , 2016, 6, 1624-35.	1.4	10
1469	Ovarian Cancer: Current Treatment and Patient Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 271-273.	0.2	5
1470	The Role of Wnt Signalling in Angiogenesis. <i>Clinical Biochemist Reviews</i> , 2017, 38, 131-142.	3.3	92

#	ARTICLE	IF	CITATIONS
1471	Reconstructing time-to-event data from published Kaplan-Meier curves. <i>The Stata Journal</i> , 2017, 17, 786-802.	0.9	36
1472	Targeting Inflammation in Ovarian Cancer Through Natural Antioxidants, Potential Therapeutic and Preventive Implications. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2687-2690.	0.5	0
1473	Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions. <i>AMIA ... Annual Symposium proceedings</i> , 2018, 2018, 1093-1102.	0.2	1
1474	TTL12 expression in ovarian cancer correlates with a poor outcome. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 239-247.	0.5	4
1475	Treatment algorithm in patients with ovarian cancer. <i>Facts, Views & Vision in ObGyn</i> , 2020, 12, 227-239.	0.5	2
1476	Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 619027.	1.6	2
1477	Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression. <i>Journal of Ovarian Research</i> , 2021, 14, 166.	1.3	4
1478	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. <i>Current Oncology Reports</i> , 2021, 23, 148.	1.8	7
1479	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
1480	Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 726278.	1.6	2
1481	Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage III&IV ovarian cancer and poor general condition. <i>Molecular and Clinical Oncology</i> , 2021, 16, 14.	0.4	1
1482	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899.	1.7	9
1483	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2123-2131.	13.9	144
1488	Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1647-1654.	0.8	1
1489	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II&IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. <i>Current Oncology</i> , 2022, 29, 231-242.	0.9	3
1491	Basics of immunotherapy for epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102283.	0.6	4
1492	Primary peritoneal serous carcinoma: a primer for radiologists. <i>Clinical Imaging</i> , 2022, 83, 56-64.	0.8	0
1494	Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 432-440.	1.0	5

#	ARTICLE	IF	CITATIONS
1495	Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2022, 29, 321-336.	0.9	5
1496	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	6
1497	Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer. <i>Experimental Cell Research</i> , 2022, 410, 112935.	1.2	1
1498	Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy. <i>Visceral Medicine</i> , 2022, 38, 109-119.	0.5	2
1499	ADAMTS8 inhibited lung cancer progression through suppressing VEGFA. <i>Biochemical and Biophysical Research Communications</i> , 2022, 598, 1-8.	1.0	11
1500	Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 803.	1.2	5
1501	Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 753-760.	1.2	3
1502	Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. , 2022, , 29-66.		1
1503	A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI " GINECO study. <i>Gynecologic Oncology</i> , 2022, 165, 30-39.	0.6	11
1504	AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma. <i>Biomedicines</i> , 2022, 10, 362.	1.4	3
1505	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	0.6	51
1506	Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100939.	0.3	7
1507	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
1508	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 522-523.	0.8	1
1509	Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 836984.	2.0	22
1510	Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer. <i>Disease Markers</i> , 2022, 2022, 1-15.	0.6	5
1511	Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models. <i>Cancers</i> , 2022, 14, 829.	1.7	12
1512	Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.0	0

#	ARTICLE	IF	CITATIONS
1513	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. <i>BMC Medicine</i> , 2022, 20, 59.	2.3	3
1514	Low-Grade Serous Carcinoma of the Ovary: The Current Status. <i>Diagnostics</i> , 2022, 12, 458.	1.3	12
1515	Erkrankungen der Adhexe. , 2021, , 461-513.		0
1516	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. Current Treatment Options in <i>Oncology</i> , 2022, 23, 15-28.	1.3	3
1518	SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52. <i>Cell Death and Disease</i> , 2022, 13, 179.	2.7	12
1519	Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. <i>Cells</i> , 2022, 11, 650.	1.8	34
1520	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. <i>Trends in Cancer</i> , 2022, 8, 426-444.	3.8	13
1521	Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2022, 22, 176.	1.1	2
1522	Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers. <i>Cancers</i> , 2022, 14, 1122.	1.7	5
1525	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
1526	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3871.	1.8	14
1527	An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGF β 2 blockade therapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3594-3601.	5.7	4
1528	Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study. <i>Journal of Obstetrics and Gynaecology</i> , 2022, 42, 2230-2234.	0.4	2
1529	Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statementâ€”A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO. <i>Cancers</i> , 2022, 14, 1295.	1.7	4
1530	Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin. <i>Frontiers in Medicine</i> , 2022, 9, 807377.	1.2	2
1531	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. <i>Frontiers in Oncology</i> , 2022, 12, 837233.	1.3	2
1532	Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. <i>BMC Cancer</i> , 2022, 22, 346.	1.1	4
1533	The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. <i>Journal of Neuro-Oncology</i> , 2022, 157, 355-364.	1.4	7

#	ARTICLE	IF	CITATIONS
1534	Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1285.	1.7	3
1535	A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. <i>Scientific Reports</i> , 2022, 12, 3803.	1.6	7
1536	Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center. <i>Gynecologic Oncology</i> , 2022, 165, 478-485.	0.6	3
1537	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100953.	0.3	1
1538	Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. <i>Clinical and Experimental Immunology</i> , 2022, 209, 4-21.	1.1	7
1539	The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 98.	1.7	16
1540	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	1.7	13
1541	Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC). <i>British Journal of Cancer</i> , 2022, 126, 1047-1054.	2.9	17
1542	Organoids and epithelial ovarian cancer – a future tool for personalized treatment decisions?. <i>Molecular and Clinical Oncology</i> , 2021, 16, 29.	0.4	2
1543	Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol. <i>BMJ Open</i> , 2021, 11, e051037.	0.8	0
1544	Treatment of Epithelial Ovarian Cancers, Fallopian Tube Cancers and Peritoneal Surface Cancers. , 2021, , 357-365.		0
1545	Traitement mÃ©dical de premiÃ¨re ligne du cancer Ã©pithÃ©lial de lâ€™ovaire de haut grade. <i>Bulletin Du Cancer</i> , 2021, 108, S5-S12.	0.6	3
1546	Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model. <i>JAMA Network Open</i> , 2021, 4, e2139573.	2.8	8
1547	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0
1548	Recent Advances in Ovarian Cancer Treatment. <i>Journal of the Nihon University Medical Association</i> , 2022, 81, 23-28.	0.0	0
1549	Appropriate Selection of PARP Inhibitors in Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 887-903.	1.3	17
1550	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 149-171.	0.5	3
1551	Complications after advanced ovarian cancer surgery – A population-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, , .	1.3	3

#	ARTICLE	IF	CITATIONS
1552	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1001-1012.	1.0	8
1553	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2911-2922.	3.2	19
1554	Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	18
1557	Measurement of VEGF Content in Exosomes and Subsequent Tumor Tubulogenesis and In Vivo Angiogenesis Functional Assays. <i>Methods in Molecular Biology</i> , 2022, 2475, 79-96.	0.4	0
1558	<i>Lactobacillus reuteri</i> Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer. <i>Radiation Research</i> , 2022, 198, .	0.7	9
1560	Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 619027.	1.6	4
1564	Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079). <i>Gynecologic Oncology</i> , 2022, 165, 413-419.	0.6	6
1565	Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2125.	1.7	7
1566	The roles and limitations of bevacizumab in the treatment of ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1120-1126.	1.0	14
1568	Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. <i>BMC Cancer</i> , 2022, 22, 508.	1.1	4
1569	Recurrent Respiratory Papillomatosis: An Update. <i>International Journal of Head and Neck Surgery</i> , 2022, 13, 1-7.	0.1	0
1570	The Value of Magnetic Resonance Diffusion-Weighted Imaging and Dynamic Contrast Enhancement in the Diagnosis and Prognosis of Treatment Response in Patients with Epithelial Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2464.	1.7	5
1571	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
1572	Anti-angiogenic therapy in ovarian cancer: current situation & prospects. <i>Indian Journal of Medical Research</i> , 2021, 154, 680.	0.4	1
1573	Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
1574	Investigation of cancer response to chemotherapy: a hybrid multi-scale mathematical and computational model of the tumor microenvironment. <i>Biomechanics and Modeling in Mechanobiology</i> , 2022, 21, 1233-1249.	1.4	5
1575	The Role of Cancer-Associated Fibroblasts in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2637.	1.7	23
1577	Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
1578	The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5793.	1.8	9
1579	Current treatment status of older patients with gynecological cancers. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 825-832.	0.6	3
1580	Is there a "low-risk" patient population in advanced epithelial ovarian cancer?: a critical analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 728-734.	0.7	3
1581	PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Cancer Investigation</i> , 2022, 40, 889-900.	0.6	1
1582	The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6911.	1.8	13
1583	Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3090.	1.7	3
1584	Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (<sc>RESPONSE</sc> trial). <i>Cancer</i> , 2022, 128, 3080-3089.	2.0	7
1585	Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003361.	1.2	0
1586	Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer " International considerations amongst upper middle- and high-income countries (UMIC and HIC). <i>Gynecologic Oncology Reports</i> , 2022, 42, 101028.	0.3	5
1587	Omentum: Friend or foe in ovarian cancer immunotherapy?. <i>International Review of Cell and Molecular Biology</i> , 2022, , 117-131.	1.6	5
1588	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	4
1589	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. <i>Facts, Views & Vision in ObGyn</i> , 2022, 14, 111-120.	0.5	1
1591	Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	0
1592	Tobacco Smoking and Survival Following a Diagnosis with Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1376-1382.	1.1	0
1593	Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536.	1.1	4
1594	Response to the letter entitled "Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers". <i>ESMO Open</i> , 2022, 7, 100534.	2.0	0
1595	Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 421-433.	0.2	2
1596	The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8125.	1.8	9

#	ARTICLE	IF	CITATIONS
1597	Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1598	Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study. <i>Gynecologic Oncology</i> , 2022, , .	0.6	5
1599	Maintenance therapy for newly diagnosed epithelial ovarian cancer—a review. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	11
1600	Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. <i>Lancet Oncology</i> , The, 2022, 23, e374-e384.	5.1	45
1601	Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers. <i>ESMO Open</i> , 2022, 7, 100533.	2.0	1
1602	Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis. <i>International Journal of Gynecological Cancer</i> . 0, . , iigc-2022-003637.	1.2	0
1603	Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant. <i>Clinical Cancer Research</i> , 2022, 28, 4660-4668.	3.2	2
1604	Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database. <i>Cancers</i> , 2022, 14, 4040.	1.7	0
1605	Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 1263-1273.	1.2	6
1606	Chemoresistance in Ovarian Cancer: The Role of Malignant Ascites. , 0, , 27-42.		1
1607	Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
1608	Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1609	Patterns of First-Line Systemic Therapy Delivery and Outcomes in Advanced Epithelial Ovarian Cancer in Ontario. <i>Current Oncology</i> , 2022, 29, 5988-6009.	0.9	0
1610	Study Design Solutions for Adjuvant and Maintenance Therapy in Cancer: Ovarian Cancer as an Example. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, .	0.3	0
1611	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. <i>Cancers</i> , 2022, 14, 3888.	1.7	56
1612	Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114504.	6.6	36
1613	Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. <i>Gynecologic Oncology</i> , 2022, 167, 11-21.	0.6	5
1614	<i>Ex Vivo</i> assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	1

#	ARTICLE	IF	CITATIONS
1615	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
1616	Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. <i>ESMO Open</i> , 2022, 7, 100558.	2.0	7
1617	Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. <i>ESMO Open</i> , 2022, 7, 100585.	2.0	13
1618	An Insight into Targeted Therapy for Ovarian Cancer. , 2022, , 2635-2656.		0
1619	Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer. <i>PharmacoEconomics - Open</i> , 2022, 6, 811-822.	0.9	4
1620	Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. <i>Diagnostics</i> , 2022, 12, 2118.	1.3	2
1621	Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2661-2669.	0.5	3
1622	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after α IFN- γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. <i>British Journal of Cancer</i> , 2023, 128, 461-467.	2.9	9
1623	EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). <i>Future Oncology</i> , 2022, 18, 3481-3492.	1.1	8
1624	Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1625	Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 818-822.	0.5	5
1626	Advances in the management of peritoneal malignancies. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 698-718.	12.5	20
1627	PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. , 0, , .		0
1628	Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer. <i>Future Oncology</i> , 0, , 00-00.	1.1	0
1630	Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge. <i>Advances in Therapy</i> , 2022, 39, 5289-5299.	1.3	6
1631	Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 102-108.	1.2	5
1632	Treatment of Advanced-Stage Ovarian Cancer. , 2022, , 105-119.		0
1633	Chemotherapeutic Protocols for the Treatment of Gynecological Cancer. , 2022, , 233-266.		0

#	ARTICLE	IF	CITATIONS
1634	Personalized Treatment in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 1-19.	0.0	0
1635	Overview of Ovarian Cancer Chemotherapy. , 2022, , 129-169.		1
1636	Targeted Molecular Therapy for Ovarian Cancer Patients. , 2022, , 179-203.		0
1637	Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. <i>Journal of Gynecologic Oncology</i> , 2022, 34, .	1.0	2
1638	Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	3
1639	Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
1641	Primary mucinous ovarian cancer: options for surgery and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1455-1462.	1.2	7
1642	Is there a role for secondary debulking in ovarian cancer? A review of the current literature. <i>Current Opinion in Obstetrics and Gynecology</i> , 2023, 35, 1-5.	0.9	3
1643	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. <i>Current Women's Health Reviews</i> , 2022, 19, .	0.1	0
1644	The current role of secondary cytoreductive surgery for recurrent ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1645	Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit): Tj ETQq0 0 OrpBT /Overlock 10 TF		
1646	Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1410-1418.	1.2	8
1647	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2022, 167, 547-556.	0.6	11
1648	Mechanisms of cancer metastasis. <i>Seminars in Cancer Biology</i> , 2022, 87, 17-31.	4.3	42
1649	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. <i>Cancers</i> , 2022, 14, 5332.	1.7	5
1650	Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3965-3974.	0.8	21
1653	A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12358.	1.8	6
1654	Superior Anticancer Potential of Nano-Paclitaxel Combined Bevacizumab Treatment in Ovarian Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 1204-1212.	0.9	1

#	ARTICLE	IF	CITATIONS
1656	Complications of disease and therapy. , 2023, , 415-442.e9.		1
1657	Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. Journal of Clinical Oncology, 2023, 41, 893-902.	0.8	16
1658	Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction. Medicina (Lithuania), 2022, 58, 1611.	0.8	4
1659	Multidisciplinary considerations in the maintenance treatment of poly(ADPâ€ribose) polymerase inhibitors for homologous recombinationâ€proficient, advancedâ€stage epithelial ovarian cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 8-16.	157.7	6
1660	Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. British Journal of Cancer, 2023, 128, 342-353.	2.9	17
1661	Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment. International Journal of Molecular Sciences, 2022, 23, 14242.	1.8	0
1662	A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of Gynecologic Oncology, 0, 34, .	1.0	1
1663	A Theoretical View of Ovarian Cancer Relapse. European Medical Journal (Chelmsford, England), 0, , 128-135.	3.0	4
1664	<i>TMED9</i> Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis. Cancer Genomics and Proteomics, 2022, 19, 692-702.	1.0	3
1665	Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives. Frontiers in Pharmacology, 0, 13, .	1.6	15
1666	Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers. Expert Opinion on Investigational Drugs, 2022, 31, 1339-1357.	1.9	0
1667	Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. Cancers, 2022, 14, 6257.	1.7	5
1668	Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment. Frontiers in Pharmacology, 0, 13, .	1.6	3
1669	Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer. JAMA Network Open, 2022, 5, e2245077.	2.8	2
1670	Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. Cancers, 2022, 14, 6010.	1.7	4
1671	Towards Personalized Management of Ovarian Cancer. Cancer Management and Research, 0, Volume 14, 3469-3483.	0.9	4
1672	Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab. International Journal of Gynecological Cancer, 2023, 33, 543-548.	1.2	1
1673	Neoadjuvant chemotherapy in advanced-stage ovarian cancer â€“ state of the art. Przegląd Menopausalny, 2022, 21, 272-275.	0.6	2

#	ARTICLE	IF	CITATIONS
1674	ROC Curve Analysis of Serum Tumor Markers in the Diagnosis of Ovarian Malignant Tumors. <i>Advances in Clinical Medicine</i> , 2022, 12, 11534-11541.	0.0	0
1676	Total Polyunsaturated Fatty Acid Level in Abdominal Adipose Tissue as an Independent Predictor of Recurrence-Free Survival in Women with Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1768.	1.8	0
1677	Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?. <i>South Asian Journal of Cancer</i> , 2022, 11, 207-212.	0.2	0
1678	Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601. <i>Anti-Cancer Drugs</i> , 2023, 34, 857-865.	0.7	2
1679	High tyrosine threonine kinase expression predicts a poor prognosis: a potential therapeutic target for endometrial carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 1352-1352.	0.7	1
1680	Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer. <i>Cancers</i> , 2023, 15, 818.	1.7	9
1681	PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 812-822.	1.2	1
1682	Can one outcome be used to predict the other outcome?. <i>Journal of the Chinese Medical Association</i> , 0, Publish Ahead of Print, .	0.6	3
1683	Wnt3a is a promising target in colorectal cancer. , 2023, 40, .		2
1684	Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers. <i>Annals of Translational Medicine</i> , 2023, .	0.7	0
1686	An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 170, 290-299.	0.6	7
1687	A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114304.	2.5	7
1688	Advances in the application of immune checkpoint inhibitors in gynecological tumors. <i>International Immunopharmacology</i> , 2023, 117, 109774.	1.7	5
1689	Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	0
1690	Molecular principles of tissue invasion and metastasis. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C971-C991.	2.1	4
1691	Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. <i>Gynecologic Oncology</i> , 2023, 172, 72-77.	0.6	3
1692	Poor-prognosis molecular subtypes in adenocarcinomas of pancreato-biliary and gynecological origin: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 185, 103982.	2.0	0
1693	PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification. <i>Modern Pathology</i> , 2023, 36, 100106.	2.9	2

#	ARTICLE	IF	CITATIONS
1694	Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer. <i>Journal of Cancer Policy</i> , 2023, 36, 100421.	0.6	2
1696	The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2022, , .		0
1697	Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. <i>IScience</i> , 2023, 26, 106020.	1.9	1
1698	Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 170, 221-228.	0.6	1
1699	Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 170, 241-247.	0.6	26
1700	Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
1701	Management of patients with advanced epithelial ovarian cancer: a European survey. <i>Archives of Gynecology and Obstetrics</i> , 0, , .	0.8	0
1702	Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors. <i>Current Cancer Drug Targets</i> , 2023, 23, 433-446.	0.8	14
1703	Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	2
1706	Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. <i>Cancers</i> , 2023, 15, 1282.	1.7	2
1707	Combination therapy with bevacizumab and a <sc>CCR2</sc> inhibitor for human ovarian cancer: An in vivo validation study. <i>Cancer Medicine</i> , 2023, 12, 9697-9708.	1.3	2
1708	Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. , 2023, 11, e005968.		17
1709	Combination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian and peritoneal cancer. <i>Medicine (United States)</i> , 2023, 102, e32880.	0.4	2
1710	A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 171, 106-113.	0.6	7
1711	Safety Analysis of Bevacizumab in Ovarian Cancer Patients. <i>Journal of Clinical Medicine</i> , 2023, 12, 2065.	1.0	1
1712	Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1713	SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation. <i>Future Oncology</i> , 0, , .	1.1	0
1714	Release of Interferon- β (IFN- β) from Probiotic <i>Limosilactobacillus reuteri</i> -IFN- β (LR-IFN- β) Mitigates Gastrointestinal Acute Radiation Syndrome (GI-ARS) following Whole Abdominal Irradiation. <i>Cancers</i> , 2023, 15, 1670.	1.7	1

#	ARTICLE	IF	CITATIONS
1715	Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. <i>Metabolites</i> , 2023, 13, 417.	1.3	1
1716	Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma. <i>JAMA Oncology</i> , 2023, 9, 675.	3.4	8
1717	Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	2
1719	PARP inhibitor era: current status and future directions. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 444-445.	1.2	1
1720	Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1721	Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 1009-1020.	0.6	4
1722	How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1723	High ATP6V1B1 expression is associated with poor prognosis and platinum-based chemotherapy resistance in epithelial ovarian cancer. <i>Oncology Reports</i> , 2023, 49, .	1.2	0
1724	Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	0
1725	An unusual presentation of ovarian carcinoma with supraclavicular lymph node and colorectal metastases leading to spontaneous rectovaginal fistula. <i>International Journal of Surgery Case Reports</i> , 2023, , 108189.	0.2	1
1726	Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients. <i>BMC Women's Health</i> , 2023, 23, .	0.8	0
1727	Exercise during CHEMotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. <i>BMJ Open</i> , 2023, 13, e067925.	0.8	1
1728	Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach. , 2022, 10, .		0
1729	The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7293.	1.8	2
1730	Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	1
1731	Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1253-1259.	1.2	2
1732	The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. , 2023, , 173-192.		0
1733	An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	1.0	0

#	ARTICLE	IF	CITATIONS
1737	A Novel Assay for Investigating the Role of Exosomes in Tumor Cell-Endothelial Cell Crosstalk. <i>Methods in Molecular Biology</i> , 2023, , 111-119.	0.4	0
1759	Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0
1780	Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options. <i>Drugs</i> , 2023, 83, 1365-1385.	4.9	0
1781	Heterogeneity and treatment landscape of ovarian carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 820-842.	12.5	3
1793	Non-serous and Rare Histologies of Ovarian Cancer. , 2023, , 43-51.		0
1795	Non-surgical Cancer Treatments. , 2023, , 131-147.		0
1826	Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. <i>Molecular Biology Reports</i> , 2024, 51, .	1.0	1
1831	Advances in the Medical Management of Ovarian Cancer. , 2023, , 345-396.		0